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Dissertation Summary
This dissertation is about two-stage adaptive designs with interim treatment selection. It includes two articles
entitled (1) ”Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection” and (2)
”Adaptive seamless designs with interim treatment selection: a case study in oncology”. Both articles are
published in the journal Statistics in Medicine.
Adaptive designs for clinical trials allow interim data-driven design modifications while maintaining the
rigor and validity of the statistical inference [1]. Design adaptations may include early stopping for efficacy,
futility or safety, reassessment of the overall sample size, adjustments to the study population (e.g. restriction
to a subpopulation), changes to endpoints or hypothesis to be tested as well as dropping or adding treatment
arms. Adaptive designs have gained considerable popularity in recent years among clinical trialists because
of their potential to improve efficiency in drug development. There are also ethical considerations that
support the use of adaptive designs; for example, adaptive designs can reduce the number of patients within
the trial who are treated with non-effective treatments. Overall, adaptive designs provide the same scientific
rigor that is required in more traditional study designs while potentially utilizing less resources. However,
while the increase in flexibility of adaptive designs offers great opportunities, it also brings limitations and
pitfalls which should be carefully assessed when adaptive designs are intended to be used in confirmatory
trials [2], [3].
In the traditional drug development process, a phase II study typically compares several treatments (e.g.
different doses of a new compound) to a control. The objective of the study is to determine whether the
development of the compound should be continued and, if so, which treatment(s) or dose(s) should be further
investigated. The phase II study also provides initial estimates of treatment effect, which are used to power
the subsequent phase III study. The phase III study is then conducted as a stand-alone confirmatory study,
disregarding all data collected on the phase II study.
One of the most appealing applications of adaptive designs is to combine phase II and phase III studies
of the traditional drug development process into a single seamless phase II/III confirmatory study (see [4]
and [5] for comprehensive summaries). Bauer and Kieser [6] proposed two-stage adaptive designs that allow
the integration of the treatment selection and the confirmatory testing of efficacy for the selected treatments
within a single study. An important feature of these designs is the fact that the treatment selection rule does
not need to be pre-specified, which gives considerable flexibility to the inherently complex interim decision
process. Hommel [7] extended Bauer and Kieser’s work to allow design modifications which include interim
changes to the primary endpoint as well as addition of experimental treatments. All these adaptive designs
(see also [8]) propose tests that control the familywise type I error rate in the strong sense; that is, the
probability that any treatment is erroneously declared significantly superior to the control is maintained below
a prespecified significance level under all possible configurations of effective and ineffective treatments.
In the next 2 sections we discuss hypothesis testing and estimation in two-stage adaptive designs with
interim treatment selection. These sections serve as a summary of the topics developed in the two articles.
1 Hypothesis testing
1.1 Two-stage combination tests
Let H0 be a one-sided null hypothesis to be tested in two sequential stages. Let α be the overall significance
level of the test. Let p and q be the p-values for testing H0 based on, respectively, stage 1 and stage 2 data.
A two-stage combination test is defined by a combination function C(·, ·), early stopping boundaries α1 and
α0 and a critical value c for the final analysis. We assume that 0 ≤ α1 < α < α0 ≤ 1 and that C(·, ·)
is monotonically increasing in both arguments. The combination test is defined as follows: if p < α1 or
p ≥ α0, we stop the trial at the end of stage 1 with, respectively, a rejection of H0 or a failure to reject H0.
If α1 ≤ p < α0, the study continues into the second stage and we reject H0 at the end of the study if and
only if C(p, q) ≤ c. The constant c, which depends on α, α1, α0 and C, is determined so that the following
level condition is satisfied:
PH0(p ≤ α1) + PH0 (C(p, q) ≤ c, α1 < p ≤ α0) ≤ α. (1)
We further assume that, under H0, the distribution of p and the conditional distribution of q given p are
stochastically larger than or equal to the uniform distribution on [0, 1]; which means that p and q satisfy
1
PH0(p ≤ x) ≤ x and PH0(q ≤ x | p) ≤ x for all 0 ≤ x ≤ 1. (2)
(Brannath et al. [9] called this property ”p clud”). This is the case, for instance, when disjoint sample units
are recruited at the different stages and conservative tests are used at each stage. The level condition (1) can
now be replaced by the equation
α1 +
∫ α0
α1
∫ 1
0
I{C(x,y)≤c}dydx = α, (3)
where the indicator function I{·} in equation (3) equals 1 when C(x, y) ≤ c and 0 otherwise. The combi-
nation test defined above is a level α test even when the design of stage 2 (e.g. sample size or test statistic)
depends on stage 1 data. The decision function of the combination test is defined as
ϕC(p, q) =
{
1 if p < α1 or both α1 ≤ p < α0 and C(p, q) ≤ c
0 otherwise. (4)
The cases ϕC = 1 and ϕC = 0 correspond, respectively, to the rejection and non-rejection of H0. Bauer
[10] and Bauer & Ko¨hne [11] suggested using the combination function given by the product of p-values
C(p, q) = pq [12]. The procedure of Proschan and Hunsberger [13] can be described by the combination
function C(p, q) = 1 − Φ ([Φ−1(1− p)]2 + [max{0,Φ−1(1− q)}]2), where α1 < α0 ≤ 0.5, 0 < p ≤ 0.5
and 0 ≤ q ≤ 1. In our work we use the weighted inverse normal combination function [14]
C(p, q) = 1− Φ [w1Φ−1(1− p) + w2Φ−1(1− q)] , (5)
where w1 and w2 are pre-defined non-negative weights that satisfy w21 + w
2
2 = 1 and Φ is the cumulative
distribution function of the standard normal distribution.
1.2 Closed testing principle
Suppose that we wish to compare k experimental treatments to a control and denote Hi; i = 1, ..., k, the
corresponding one-sided null hypotheses. In order to account for the multiplicity of the testing procedure,
we use the closed testing principle [15], which works as follows. We first must define level α tests for all
intersection hypothesesHΨ = ∩i∈ΨHi, whereΨ ⊆ F = {1, ..., k}. Then, an individual null hypothesisHj ,
j ∈ F , can be rejected at multiple level α if and only if, for all subsets Ψ ⊆ F containing j, we have that the
hypothesis HΨ has been rejected at level α. The testing procedure described above protects the family-wise
error rate at level α in the strong sense; that is, the probability of rejecting at least one true null hypothesis is
bounded above by α, under any configuration of true and false null hypotheses.
Let pi be the p-value associated with the testing of individual null hypothesis Hi; i = 1, ..., k. Let
HΨ = ∩i∈ΨHi be an intersection hypothesis, where Ψ ⊆ F . Let r = |Ψ| be the cardinality of Ψ. A p-value
for testing HΨ can be defined in several ways:
pΨ = min
[
1, rmin
i∈Ψ
(pi)
]
(Bonferroni test)
pΨ = 1−
[
1−min
i∈Ψ
(pi)
]r
(Sidak test)
pΨ = min
i∈Ψ
r
i
p(i) (Simes test)
pΨ = min
i∈Ψ
(r + 1− i)p(i) (Hochberg test)
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where p(i) denotes the i-th smallest p-value, for i ∈ Ψ. For the case of (approximately) normally distributed
test statistics, the Dunnett test [16] can be used to test the intersection hypotheses. The Dunnett test accounts
for the correlation between the test statistics due to the fact that the different treatments are compared to the
same control.
As an example, consider the case of two treatments. LetH1 andH2 be the individual null hypotheses and
let p1 and p2 be the corresponding p-values. We must construct a test for the intersection hypothesis H1 ∩
H2. By Hochberg’s procedure, the p-value pint = min{2p(1), p(2)} = min{2min{p1, p2},max{p1, p2}}
provides a conservative test for H1 ∩H2. By the closed testing principle, a multiplicity-adjusted p-value for
testing Hj is given by pj,adj = max{pj , pint}; j = 1, 2.
1.3 Combination tests applied after interim treatment selection
Let us now consider the comparison of k experimental treatments to a control in two stages. Let Hi; i ∈
F = {1, ..., k} denote the one-sided null hypotheses. Let pΨ be the stage 1 p-value for testing the intersection
hypothesis HΨ, Ψ ⊆ F , computed by one of the methods described in 1.2. Let G ⊆ F be the indices of the
treatments selected at the interim analysis to continue into the second stage. For all hypotheses HΨ, Ψ ⊆ G,
let qΨ be the corresponding stage 2 p-value. For all other hypotheses HΨ, Ψ ⊆ F , we define
qΨ = qΨ∩G
where q∅ = 1. These p-values are conservative for testing HΨ because of the ”p clud” condition
PHΨ (qΨ ≤ x | pΨ) ≤ PHΨ∩G (qΨ∩G ≤ x | pΨ∩G) ≤ x.
Now, for each Ψ ⊆ F , the intersection hypothesis HΨ is rejected if and only if ϕC(pΨ, qΨ) = 1, where
ϕC(·, ·) is defined in (4) for a pre-specified combination function C(·, ·), early stopping boundaries α0 and
α1 and critical value c, which satisfy (3) for a given overall significance level α. Finally, by the closed
testing principle, an individual hypothesis Hj , j ∈ F is rejected at multiple level α if and only if all inter-
section hypotheses HΨ, with Ψ ⊆ F and j ∈ Ψ are rejected at level α with their combination tests; that is
ϕC(pΨ, qΨ) = 1.
As an example, let us consider again the case of two treatments. Suppose that, after stage 1, treatment 1
is selected to continue into stage 2 and treatment 2 is stopped. At the end of the study we have p1 and p2, the
stage 1 p-values for testing H1 and H2, and q1, the stage 2 p-value for testing H1. We set q2 = 1, because
there is no stage 2 data comparing treatment 2 with control. We compute the stage 1 p-value for testing the
intersection hypothesis H1 ∩ H2 using Hochberg’s method by pint = min{2min{p1, p2},max{p1, p2}}.
The stage 2 p-value for the intersection hypothesis is set to qint = q1. Finally, H1 is rejected at the end of the
study if both ϕC(p1, q1) = 1 and ϕC(pint, qint) = 1. In the case that both treatments are selected to continue
into stage 2, q2 would be the stage 2 p-value for testing H2 and qint = min{2min{q1, q2},max{q1, q2}}
would be the stage 2 p-value for testing H1 ∩H2. Hypothesis H2 could be rejected at the end of the study if
and only if both ϕC(p2, q2) = 1 and ϕC(pint, qint) = 1.
1.4 Time-to-event setting
In this section, we follow ideas described in [17]. Suppose that we are interested in comparing k experimental
treatments to a control in 2 stages with regards to a time-to-event endpoint. Let Hi be the null hypothesis
of no difference in the survival distribution of the time-to-event endpoint between treatment i and control;
i = 1, ..., k. Let us assume one-sided alternative hypotheses that the treatments prolong the time to an event
compared to control. A common test applied in this situation is the log-rank test, which we now describe. Let
dij be the cumulative number of events observed at the end of stage j among patients recruited into treatment
i and control; i = 1, ..., k and j = 1, 2. Let Nijt and N0jt be the number of patients at risk, respectively, in
treatment i and control at stage j when the t-th event occurred in treatment i or control. Under the assumption
of no ties, the log-rank statistic at stage j for the comparison of treatment i with control is given by
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Zij =
∑dij
t=1 Iijt − NijtNijt+N0jt√∑dij
t=1
NijtN0jt
(Nijt+N0jt)
2
; i = 1, ..., k j = 1, 2,
where Iijt = 1 if the event ocurred in the treatment i and 0 otherwise. Note that ’large’ negative values of Zij
are evidence against Hi. For fixed dij , Zij has an asymptotic normal distribution with variance 1 and mean√
dij
√
ri
ri+1
ln θ, where θ is the true hazard ratio between treatment i and control and ri is the ratio between
the number of patients recruited into treatment i and control groups respectively [18]. If the numbers at risk
in each treatment group remain nearly equal over time, as it is to be expected under the null hypothesis, then
Nijt ≈ N0jt and we can use the approximation
dij∑
t=1
NijtN0jt
(Nijt +N0jt)
2 ≈
dij
4
.
The sequence of test statistics Zi1, Zi2 approximately has an independent and normally distributed incre-
ments structure (see, e.g. [19], [20]). Thus,
Z∗i2 =
√
di2Zi2 −
√
di1Zi1√
di2 − di1
is independent of Zi1 and we have that
√
di2Zi2 =
√
di1Zi1 +
√
di2 − di1Z∗i2;
for i = 1, ..., k. The stagewise p-values for the comparison of treatment i with control are calculated by
pi = Φ(Zi1), and qi = Φ(Z∗i2).
Stagewise p-values for the intersection hypotheses can be computed as described in section 1.3 using one of
the methods described in section 1.2. We suggest applying the inverse normal combination function C given
in 5, where w1 =
√
ξ1
ξ2
, w2 =
√
ξ2−ξ1
ξ2
and ξ1 and ξ2 are the planned number of events among all treatment
arms after stage 1 and stage 2 respectively. The decision function is given in (4), where C, α0, α1 and c
satisfy the level equation (3). If the observed numbers of events di1 and di2 are equal to, respectively, the
planned numbers of events ξi1 and ξi2, then the inverse normal test statistic at the end of the study equals the
log-rank test statistic. In order to preserve the type I error rate, the weights w1 and w2 must be pre-fixed and
remain unchanged throughout the study.
Scha¨fer & Mu¨ller [21] extended the adaptive design methodology to time-to-event data by using the
conditional error approach [13] and applying the independent increments structure of the log-rank statistics
described above. But Bauer & Posch [22] pointed out that caution must be exercised when applying these
flexible designs: in the particular setting of a two-stage design with treatment selection after the first stage,
it means that stage 2 p-values for the comparison of the selected treatments with the control at the end of the
study cannot be influenced by surrogate information of stage 1 patients who are at risk at the interim treatment
selection analysis. Therefore, the standard testing procedure of Scha¨fer & Mu¨ller [21] that combines stage-
wise p-values computed from increments of the log-rank statistic (see also [17]) may not protect the type I
error rate unless treatment selection is based only on the score statistics of the primary endpoint, which is
unrealistic in practice.
In the context of enrichment designs, Jenkins et al. [23] proposed a testing procedure that preserves type I
error rate while allowing all information collected until the interim analysis to be used for treatment selection.
Ko¨nig et al. [24] suggested a testing procedure based on a modification of the classical Dunnett [16] test
which guarantees strict control of type I error rate without imposing any restrictions on the information that
can be used at the interim analysis for treatment selection purposes. The method by Ko¨nig et al. [24] has,
however, not been developed for time-to-event data so far. Di Scala and Glimm [25] extended the classical
Dunnett [16] test to time-to-event data for adaptive seamless designs with interim treatment selection.
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In the second article of this thesis, the planning of an oncology clinical study with an adaptive seamless
phase II/III design is discussed. Two regimens of an experimental treatment are compared to a control at
an interim analysis and the most-promising regimen is selected to continue, together with control, until the
end of the study. Since the study’s primary endpoint will be immature at the regimen selection analysis, it is
of interest to investigate whether the incorporation of surrogate information can help improving the regimen
selection process and thus the study’s probability of success. To this end, designs are considered which
include the primary as well as surrogate endpoints (e.g. exposure to treatment) in the regimen selection
analysis. At the end of the study, testing of efficacy is carried out to compare the selected regimen to the
control with respect to the primary endpoint, utilizing all relevant data collected both before and after the
interim analysis. Since the operating characteristics of these designs depend on the specific regimen selection
rules considered, on the correlation between primary and surrogate endpoints and on the true standardized
mean difference of the surrogate endpoint(s), benchmark scenarios are proposed in which a perfect surrogate
and no surrogate is used at the regimen selection analysis. The operating characteristics of these benchmark
scenarios provide a range where those of the actual study design are expected to lie.
The above three approaches ([21],[23],[24]) were assessed with regard to power and type I error rate for
testing the primary null hypothesis comparing the selected regimen to the control at the end of the study. The
standard testing procedure that combines stage-wise p-values based on the independent increments prop-
erty of the log-rank statistic (Scha¨ffer & Mu¨ller [21], Wassmer [17]) did not protect the type I error when
treatment selection was based on exposure and correlation between exposure and survival was high. One
possibility would be to adjust the significance level to achieve type I error control to the specified level α
for the perfect surrogate approach, which provides an upper bound for the type I error. This adjustment will
of course affect the power of the study. The procedure proposed by Jenkins et al. [23] protects the type I
error when testing the primary endpoint as long as the follow-up of stage 1 patients remains unchanged after
the regimen selection analysis, which may be difficult to achieve in practice. If, for instance, it is decided to
discontinue treatment in the dropped arm (e.g. for ethical reasons), this may have an impact on the type I
error rate: (i) because the p-value for the comparison of the dropped regimen with the control may no longer
be uniformly distributed under the null hypothesis (if e.g. these patients drop out and get an alternative
treatment) and (ii) because this adaptation may affect the time point of the final analysis. The conservative
Dunnett test procedure suggested in [24] protects the type I error without placing any strong restrictions to
the study design. It only requires that the recruitment of the second stage patients is independent from the
interim data. It can also be extended to a procedure for testing primary and secondary endpoints which pro-
tects the multiple type I error rate. Moreover, its conservatism provides a safeguard against unintended type I
error inflations, for instance, due to unintended changes in the recruitment rate. Changes to treatment and/or
follow-up of patients in the dropped arm do not affect the type I error as these patients are not used in the
final analysis. The conservative Dunnett test also allows construction of simultaneous confidence intervals.
A disadvantage of the Dunnett procedure is that it does not permit data driven changes of the preplanned
overall event number. All three procedures have similar performance with regard to the power to reject the
primary hypothesis for the comparison of the selected treatment to the control at the end of the study.
We have not found a clear advantage with regard to power in using adaptive designs compared to a 3-arm
phase III design. However, even though the probability of correct treatment selection is maximized with the
3-arm phase III design, an adaptive design allows us to select a treatment early, avoiding an unnecessary
large recruitment of patients to the non-selected arm, which is important from an ethical and practical point
of view. If efficacy differences in survival are reflected by substantial differences in exposure, then a selec-
tion rule based on exposure can improve power compared to a rule based on survival only. However, power
could be dramatically reduced when the surrogate endpoint is not able to select the correct treatment with
high probability, independently of how highly correlated the primary and surrogate endpoints may be. A
solution to this problem could be selection rules that incorporate both, exposure and the immature primary
endpoint. How to combine these two endpoints in a sensible selection rule is an interesting open research
question. Treatment selection rules should always include the primary endpoint independently how imma-
ture the primary endpoint may be. In practice, selection rules will also incorporate safety parameters such as
overall death rates, adverse events, serious adverse events, treatment withdrawals and exposure to treatment,
which may be important drivers in the dosing decision. One design feature we have not considered in our
investigation is the possibility to continue with both experimental arms to the end of the study if interim re-
sults do not show a clear advantage for one or the other. In this situation, the conservative Dunnett procedure
could inflate the type I error because the overall number of events could not be pre-fixed.
5
2 Estimation
2.1 One-stage design
Consider the comparison of k ≥ 2 treatments in a single-stage design. At the end of the study, we select the
treatment that has the largest observed effect and we wish to estimate the effect of this treatment. We assume
that we have n independent observationsXij ∼ N(θi, σ2), j = 1, ..., n in each treatment group i, i = 1, ..., k
and that σ2 is the common and known variance. For simplicity, we do not consider a control treatment but
the methods presented here can be extended to designs with a control arm. We let Xi =
∑n
j=1Xij/n be
the sample mean of the observations in group i. We denote with S ∈ {1, ..., k} the index of the selected
treatment so that XS = max{X1, ..., Xk}. The objective is to estimate θS , which is a random variable that
depends on X1, ..., Xn. The performance of a generic estimator QS of θS can be assessed by the selection
bias bθ(QS) = Eθ[QS − θS ] and the selection mean squared error MSEθ(QS) = Eθ
[
(QS − θS)2
]
, as it
was originally introduced by Putter & Rubinstein [26]. Both quantities depend on the unknown mean vector
θ = (θ1, ..., θk).
The maximum-likelihood estimator (MLE) for the effect of the selected treatment, θS , is the sample mean
of the selected treatment, XS , which ignores the fact that a selection has been performed. This estimator has
well known undesirable properties. It has positive selection bias and it is highly missleading when all true
treatment effects are equal and the number of treatments being compared is large, asXS → ∞ in probability
when k → ∞ for θ1 = ... = θk. On the one hand, Putter & Rubinstein [26] showed that there is no unbiased
estimator for θS . On the other hand, Brown [27] proved that XS is an admissible estimator of θS ; that is, no
other estimator of θS can have smaller MSE than XS for all values of the parameters θ1, ..., θk. Therefore,
the aim should be to find estimators of θS that have smaller bias than the MLE and that at the same time
improve upon the MLE with respect to the MSE in realistic scenarios.
In order to better assess the magnitude of the problem, it is useful to know for which values of the
parameters the selection bias and MSE of the MLE will be largest. Cohen & Sackrowitz [28] showed that
the MSE is largest when all true effects are equal. In the first paper of this thesis, we prove that selection bias
is also maximal in this case.
Hwang [29] focused on single-stage multi-armed trials with k ≥ 4 experimental treatments and proposed
Lindley’s estimator [30] for estimating the mean θS of the treatment S with largest average. This gives the
estimator
QLS = Cˆ+XS + (1− Cˆ+)X¯ where Cˆ+ = max
(
Cˆ, 0
)
with Cˆ = 1− (k − 3)σ
2
n
∑k
j=1(Xj − X¯)2
. (6)
Lindley’s estimator shrinks the conventional MLE XS towards the overall sample mean X¯ =
∑k
i=1Xi/k.
One can see by heuristic arguments that this estimator is reasonable. For θ1 = ... = θk, the overall mean
X¯ is the most-efficient estimator for θS and n
∑k
j=1(Xj − X¯)2/σ2 ∼ χ2(k − 1) has its mode at k − 3.
Therefore Cˆ+ is likely to be close to 0 in which case shrinkage to X¯ is strong. If θ1, ..., θk are far from each
other, i.e. maxi =j |θi − θj | is large, then
∑k
j=1(Xj − X¯)2 is likely to be large and Cˆ+ is likely to be close
to 1. As a consequence QLS is close to XS which is reasonable because the bias of XS is small for large
maxi =j |θi − θj |.
Hwang considered the problem from an empirical Bayesian point of view and showed thatQLS uniformly
improves XS within this frame work. To this end, he assumed conjugate normal priors θi ∼ N(μ, τ2)
and that Xi | θi ∼ N(θi, σ2/n), i = 1, ..., k, for a known variance σ2. These assumptions correspond to a
random effects model for the replicatesXij with treatment as a random factor and a known residual variance
σ2. The Bayes estimator for θS is
QBS = E [θS |X1, ..., Xk] = CXS+(1−C)μ , where C = nτ2/(σ2+nτ2) = 1−σ2/(σ2+nτ2) . (7)
The estimator QBS coincides with the best linear unbiased predictor (BLUP) for the random effects model
and is known to have minimal Bayes risk
Rμ,τ (Q
B
S ) =
∫ ∞
−∞
· · ·
∫ ∞
−∞
Eθ
(
QBS − θS
)
φ
(
θ1 − μ
τ2
)
· · ·φ
(
θk − μ
τ2
)
dθ1 · · · dθk .
The Bayes risk is the integral of MSEθ(QBS ) with regard to the normal prior distribution for θ1, . . . , θk.
Replacing in (7) the unknown μ with its mean unbiased estimator X¯ and the unkown C with the positive part
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of Cˆ = 1− (k− 3)σ2/[n∑kj=1(Xj − X¯)2] (Cˆ can be shown to be mean unbiased for C) leads to Lindley’s
estimator (6). Hwang verified the following domination result.
Theorem 2.1 If k ≥ 4, then QLS has uniformly smaller Bayes risk than XS , i.e. Rμ,τ (QLS) ≤ Rμ,τ (XS) for
all N(μ, τ2)-distributed priors.
2.2 Two-stage design
Consider now two-stage designs with treatment selection at the end of stage 1. Let X1, ..., Xk be the stage 1
sample means, based on a sample size of n1 subjects per group (equal for all treatments). Assume that S is
the index of the best-performing treatment at the interim analysis, i.e. XS = max(X1, ..., Xk). Suppose
further that n2 subjects are recruited in the selected treatment arm in the second stage. Let YS be the
stage 2 sample mean for the selected treatment. The overall MLE at the end of the study can be written
as QMLES = tXS + (1 − t)YS where t = n1/(n1 + n2). Note that bθ(QMLES ) = tbθ(XS) because YS is
an unbiased estimator of θS . Therefore, the larger the first stage sample size the larger the bias. Note that
the larger the first stage sample size the better the treatment selection at the end of stage 1 because of the
larger amount of information to make the treatment selection. This dichotomy between bias and selection
was pointed out by Bauer et al [31].
Cohen & Sacrowitz [32] proposed a two-stage estimator of the mean of the best-performing treatment
that is conditionally unbiased given the order statistics of the first-stage sample means and has uniformly
minimum variance among all such conditionally unbiased estimators. Their estimator is of course also
unconditionally unbiased. Bowden & Glimm [33] extended Cohen & Sackrowitz’s work to unequal group
variances and selecting not only the most-promising but also j-th most-promising treatment for j ≤ k.
Stallard & Todd [34] considered the mean bias of the MLEs conditional on the selection of treatment
S, i.e. bθ(i;S) = Eθ(QMLEi |S) for i = 1, . . . , k, and derived numerical expressions for these conditional
selection biases. They suggested to subtract the selection bias bθ(i;S) from each MLEQMLEi . Since bias de-
pends the unknown θ = (θ1, . . . , θk), only an estimator of the conditional biases can be subtracted. Stallard
& Todd proposed an iterative approach similar to the iterative scheme in Whitehead [35].
In the first paper of this thesis, we extend Hwang’s domination result [29] to two-stage designs with
treatment selection whereby we focus on the case of selecting a single experimental treatment at the interim
analysis. We define for k ≥ 4 the following two-stage version of Lindley’s estimator
QLS = tQ
L,1
S + (1− t)YS (8)
whereQL,1S is Lindley’s estimator (6) from the first stage data. Since the second stage continues with only one
experimental treatment there is no need to adjust the second stage MLE. We show that Hwang’s domination
result also applies to the two-stage version (8) of Lindley’s estimator.
Theorem 2.2 If k ≥ 4, then Lindley’s two-stage estimator (8) has uniformly smaller Bayes risk than QMLES ,
i.e. Rμ,τ (QLS) ≤ Rμ,τ (QMLES ) for all N(μ, τ2)-distributed priors.
Lindley’s estimator is defined only for k ≥ 4 whereas the Bayes estimator (7) is defined and optimal with
regard to the Bayes risk for all k ≥ 2. The restriction of Lindley’s estimator to k ≥ 4 is caused by the use
of the mean unbiased estimator Cˆ for C which is defined only for k ≥ 4. It appears natural to consider the
Bayes estimator with another estimator for C when k = 2, 3. To this end, we suggest to adopt the random
effects model point of view and use for the first stage estimator the standard estimator of the BLUP which
is defined for all k ≥ 2 and equals Lindley’s estimator (6) with k − 3 replaced by k − 1 (see e.g. Searle,
Casella and McCulloch [36]). More precisely, we consider replacing Lindley’s estimator QL,1S in (8) by the
estimated BLUP from the random effects model for the first stage data. No domination result is known for
this type of estimator.
We have investigated by simulation studies the performance of the two-stage version of Lindley’s es-
timator and the estimated BLUP and have found favorable properties of these estimators in comparison to
the MLE and the bias-adjusted estimators of Cohen & Sackrowitz [32] and Stallard & Todd [34]. Whereas
Cohen & Sackrowitz’s estimator perfectly removes the selection bias, it has increased variance in a way that
the mean square error is generally larger than for the MLE. Stallard & Todd’s estimator was found to have
the tendency for an overcorrection of bias, at least in the two-stage setting, and it is also in general inferior
to the MLE and shrinkage estimators in terms of mean square error. The two-stage shrinkage estimators did,
on the one hand, reduce selection bias of the MLE substantially (although not removing it completely) and,
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on the other hand, improved or was equivalent to the MLE in terms of mean square error. Since we believe
that mean square error is more appropriate as measure of precision than the bias itself, we suggest using
shrinkage estimators to deal with the problem of selection bias.
References
[1] Dragalin, V. Adaptive designs: terminology and classification. Drug Information Journal 2006; 40 :
425-435.
[2] Reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis
plan. Committe for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMEA),
2006. Doc. Ref. CHMP/EWP/2459/02.
[3] Guidance for industry: adaptive design clinical trials for drugs and biologics. U.S. Department of Health
and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research
(CDER), Center for Biologics Evaluation and Research (CBER), 2010.
[4] Bauer P. and Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug
Discovery Today 2004; 9 : 351-357.
[5] Bretz F., Ko¨nig F., Brannath W., Glimm E. and Posch M. Adaptive designs for confirmatory clinical
trials. Statistics in Medicine 2009; 28 : 1181-1217.
[6] Bauer P. and Kieser M. Combining different phases in the development of medical treatments within a
single trial. Statistics in Medicine 1999; 18 : 1833-1848.
[7] Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 2001;
43 : 581-589.
[8] Posch M., Ko¨nig F., Branson M., Brannath W., Dunger-Baldauf C. and Bauer P. Testing and estimation
in fexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 24 :
3697-3714.
[9] Brannath, W., Posch, M. and Bauer, P. Recursive combination tests. Journal of the American Statistical
Association 2002; 97 : 236-244.
[10] Bauer, P. (1989). Multistage testing with adaptive designs (with discussion). Biometrie und Informatik
in Medizin und Biologie 1989; 20 : 130-148.
[11] Bauer, P. and Ko¨hne, K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;
50 : 1029-1041.
[12] Fisher R. A. Statistical methods for research workers. London: Oliver & Boyd.
[13] Proschan, M.A. and Hunsberger, S.A. Designed extension of studies based on conditional power. Bio-
metrics 1995; 51 : 1315-1324.
[14] Lehmacher, W., and Wassmer, G. Adaptive sample size calculations in group sequential trials. Biomet-
rics 1999; 55 : 1286-1290.
[15] Marcus R., Peritz E., Gabriel K.R. On closed testing procedures with special reference to ordered
analysis of variance. Biometrika 1976; 63 : 655-660.
[16] Dunnett D.W. A multiple comparison procedure for comparing several treatments with a control. Jour-
nal of the American Statistical Association 1955; 50 : 1096-1121.
[17] Wassmer G. Planning and analyzing adaptive group sequential survival trials. Biometrical Journal
2006; 48 : 714-729.
[18] Schoenfeld D. A. The asymptotic properties of nonparametric tests for comparing survival distribu-
tions. Biometrika 1981; 68 : 316-319.
8
[19] Tsiatis, A. A. (1981). The asymptotic joint distribution of the efficient scores test for the proprtional
hazards model calculated over time. Biometrika 1981; 68 : 311-315.
[20] Tsiatis, A. A. (1982). Repeated significance testing for a general class of statistics used in censored
survival analysis. Journal of the American Statistical Association 1982; 77 : 855-861.
[21] Scha¨fer H. and Mu¨ller H. Modication of the sample size and the schedule of interim analyses in survival
trials based on data inspections. Statistics in Medicine 2001; 20 : 3741-3751.
[22] Bauer P. and Posch M. Letter to the Editor: Modification of the sample size and the schedule of interim
analyses in survival trials based on data inspections. Statistics in Medicine 2004; 23 : 1333-1335.
[23] Jenkins M., Stone A. and Jennison, C. An adaptive seamless phase II/III design for oncology trials
with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10 :
347-356.
[24] Ko¨nig F., Brannath W., Bretz F. and Posch M. Adaptive Dunnett tests for treatment selection. Statistics
in Medicine 2008; 27 : 1612-1625.
[25] Di Scala L. and Glimm E. Time-to-event analysis with treatment arm selection at interim. Statistics in
Medicine 2011; 30 : 3067-3081.
[26] Putter J, Rubinstein D. On estimating the mean of a selected population. Technical Report No 165,
University of Wisconsin, Department of Statistics, 1968.
[27] Brown L. D. Personal communication to J. T. Hwang. 1987.
[28] Cohen A., Sackrowitz H.B. Estimating the mean of the selected population. Statistical Decision Theory
and Related Topics III 1982; 1 : 243-270.
[29] Hwang J.T. Empirical Bayes estimation for the means of the selected populations. The Indian Journal
of Statistics 1993; 55 : 285-311.
[30] Lindley D. V. Discussion of Professor Stein’s paper ”Confidence sets for the mean of a multivariate
normal distribution”. Journal of the Royal Statistical Society, Serie B 1962; 24 : 265-296.
[31] Bauer P, Koenig F, Brannath W, Posch M. Selection and bias - two hostile brothers. Statistics in
Medicine 2010; 29 : 1-13.
[32] Cohen A., Sackrowitz H.B. Two stage conditionally unbiased estimators of the selected mean. Statistics
& Probability Letters 1989; 8 : 273-278.
[33] Bowden J., Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical
Journal 2008; 4 : 515-527.
[34] Stallard N., Todd S. Point estimators and confidence regions for sequential trials involving selection.
Journal of Statistical Planning and Inference 2005; 135 : 402-419.
[35] Whitehead J. On the bias of maximum-likelihood estimation following a sequential test. Biometrika
1986; 73 : 573-81.
[36] Searle, S.R., Casella G. and McCulloch C. Variance Components. Wiley Series in Probability and
Statistics 1992.
9
Special Issue Paper
Received 15 May 2011, Accepted 1 April 2012 Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/sim.5463
Shrinkage estimation in two-stage
adaptive designs with midtrial
treatment selection‡
Máximo Carrerasa and Werner Brannathb*†
We consider the problem of estimation in adaptive two-stage designs with selection of a single treatment arm
at an interim analysis. It is well known that the standard maximum-likelihood estimator of the selected treat-
ment is biased. We prove that selection bias of the maximum-likelihood estimator is maximal when all treatment
effects are equal and the most-promising treatment is selected. Furthermore, we consider shrinkage estimation
as a solution for the selection bias problem. We thereby extend previous work of Hwang on Lindley’s estimator
for single-stage multi-armed trials with four or more treatments and post-trial treatment selection. Following
Hwang’s ideas, we show that a simple two-stage version of Lindley’s estimator has uniformly smaller Bayes risk
than the maximum-likelihood estimator when assuming an empirical Bayesian framework with independent
normal priors for the group means. For designs that start with two or three treatment groups, we suggest using a
two-stage version of the common estimator of the best linear unbiased predicator of the corresponding random
effects model. We show by an extensive simulation study that the shrinkage estimators perform well compared
with maximum-likelihood and previously suggested bias-adjusted estimators in terms of selection bias and mean
squared error. Copyright © 2012 John Wiley & Sons, Ltd.
Keywords: best linear unbiased predictor (BLUP); Bayes risk; clinical trial; empirical Bayes; Lindley’s
estimator; random effects model; seamless phase II/III design; selection bias; selection mean
squared error
1. Introduction
There has been increasing interest over the last years in two-stage clinical trial designs in which k > 2
experimental treatments are compared with a control in an interim analysis after a first stage and the
most-promising treatments are selected at the interim analysis to continue, together with the control,
into a second stage (for reviews, see, e.g., [1, 2]). Hypothesis testing methods have been developed that
allow the treatment selection rule to be defined at the interim analysis integrating all available infor-
mation, including information external to the study, without affecting the overall multiple type I error
rate [3–6]. Whereas testing can be viewed as a resolved issue, the equally important task of parameter
estimation still lacks a satisfactory solution (e.g., [5, 7]). In this article, we provide a solution to the
important problem of point estimation of the effect of the selected treatments at the end of such trials by
considering shrinkage methods.
It is well known that maximum-likelihood estimators (MLEs) exhibit statistical bias, and therefore,
attempts have been undertaken to remove or reduce bias of treatment effect estimators in designs with
midtrial treatment selection [8–11]. Although these methods are successful in removing bias [8, 11] or
at least reducing it substantially [9, 10], they do not provide estimators with generally improved mean
squared error (MSE) compared with the MLE. We will illustrate by simulation results that they can even
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lead to an inflation of the MSE. Because the MSE is a combination of bias and variance and more rea-
sonably describes the precision of an estimator than the bias by itself, this implies that bias reduction
with the current methods may come for a too high price of a substantial increase in the variance and
these methods are not recommendable for practical use. The focus of our work is on utilizing estimation
methods that reduce the bias and, equally important, control the MSE of estimation.
There are two sources of statistical estimation bias in designs with interim treatment selection. One
type of bias is produced by the data-dependent sample size induced by the treatment selection process.
Because recruitment to a specific treatment arm is stopped if the observed interim effect is small (namely,
smaller than the maximum treatment effect), there is a tendency to underestimate the treatment effect of
that arm. This is similar to the bias that is produced by a stopping for futility rule. This negative bias
applies to each of the k treatment estimators and becomes apparent when we report effect estimates for
all treatments simultaneously, irrespective of which treatments have been selected, with the use of the
interim estimate for the dropped treatments. We call this negative bias the always-reporting bias (see [7]
for simulation results).
Another type of bias is caused by the selection process itself: when selecting the apparently most-
efficient treatment at the interim analysis, the interim estimator of the selected treatment equals the
maximum of all interim estimators and hence is positively biased. This positive bias is carried forward
to the second stage when using data from both stages in the final estimator. This type of bias is called
selection bias. It usually remains relevant even though it is diluted by the independent second-stage sam-
ple for the selected treatment (e.g., [7]). In contrast to the negative always-reporting bias, the positive
selection bias indicates that treatment effects are overestimated.
The contradictory sign of always-reporting and selection bias may appear confusing. However, it has
a simple and important implication. It implies that selection bias is solely caused by our focus on the
selected treatment and our neglect of the other treatment effect estimators. We may therefore ask whether
we can improve the MLE of the selected treatment with regard to bias and MSE by using an estimator
that is computed from all available information including the data from the dropped treatment groups. If
the different treatments are different doses of a medicine, then a way to utilize all data is to fit a dose–
response model to the complete data and predict the mean efficacy of the selected treatment from this
model. In this paper, we follow an alternative and more general approach, namely, we consider using a
shrinkage estimator.
Our focus on shrinkage methods has been motivated by two references. The first reference is Chapter
4.5 of Harrell’s modeling strategy book [12, p. 62–63] in which the selection bias problem is used as a
motivating example for shrinkage techniques in regression analysis. He considered k group means that
satisfy the analysis of variance assumptions and draws a plot of the ordered group means against their
ranks. This always gives an increasing curve whose slope is strongly up biased because of selection bias.
Shrinkage in the regression modeling context means to shrink down the slope towards zero to reduce
the selection bias. This points to an interesting connection between selection bias and the problem of
overfitting. The other reference is a paper of Hwang [13] who considered Lindley’s shrinkage estimator
[14] in the same context and showed strong preferable properties with regard to the MSE in compari-
son with the MLE. We will review Hwang’s result in Section 2. Both references apply to the setup of
multi-arm clinical trials where treatments are selected at the end of the trial, that is, designs with a single
stage. In this article, we propose an extension of shrinkage estimation to two-stage designs with midtrial
treatment selection.
We organize the paper as follows. In Section 2, we review the definition of selection bias and selection
MSE in the context of single-stage multi-armed trials where treatment selection is performed at the end
of the trial. We also prove that selection bias of the MLE is maximal when all treatment effects are equal
and the best-performing treatment is selected. This fact has frequently been observed; however, no proof
has been given yet. We then review Hwang’s result on Lindley’s estimator. In Section 3, we introduce
a two-stage version of the shrinkage estimator and show that Hwang’s result essentially remains valid
for two-stage designs with midtrial selection of a single treatment. In Section 4, we present simulation
results and conclude with a discussion in Section 5. We provide proofs in Appendix A.
2. Selection bias and mean squared error in single-stage designs
To introduce the problem and to review Hwang’s result, we start by considering a randomized single-
stage design with k parallel treatment arms where the apparently most-efficacious treatment is selected
at the end of the trial. We assume n independent observations Xij  N.i ; 2/, j D 1; : : : ; n, in
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each treatment group i , where 2 is the common and known variance. For simplicity, we do not con-
sider a control treatment, but the methods proposed in this article can easily be extended to designs
with a control arm. We will discuss this in Section 5. We let Xi D PnjD1 Xij =n be the sample
mean of the observations in group i . Denoting by S 2 f1; : : : ; kg the index of the selected treat-
ment, we have XS D max.X1; : : : ; Xk/. The objective is to estimate or rather predict S , which is
a random variable that depends on X1; : : : ; Xk . The performance of a generic estimator QS of S
will be assessed by the selection bias b .QS / D E ŒQS  S  and the selection mean squared error
MSE .QS / D E Œ.QS  S /2 D Var .QS /Cb2 .QS /, as originally introduced in [15]. Both quantities
depend on the unknown mean vector  D .1; : : : ; k/.
2.1. Maximum-likelihood estimator of S
The MLE for the effect of the selected treatment, S , is the sample mean of the selected treatment,
XS , which ignores the fact that a previous selection has been performed. This estimator has well-known
undesirable properties. It has positive selection bias and is highly misleading when all true treatment
effects are equal and the number of treatments being compared is large, as XS ! 1 in probability when
k ! 1 for 1 D    D k . On the other hand, Brown (personal communication to Hwang, [13]) proved
that XS is an admissible estimator of S ; that is, no other estimator of S can have smaller MSE than
XS for all values of the parameters 1; : : : ; k . Therefore, the aim should be to find estimators of S that
improve upon the MLE with respect to the MSE in realistic scenarios.
To better assess the magnitude of the problem, it is useful to know for which values of the parameters
the selection bias and MSE of the MLE will be largest. Cohen and Sackrowitz [16] proved that the MSE
is largest when all true effects are equal. We present here a theorem that states that the selection bias
is also maximal in this case. Although intuitively clear and observed in numerous simulation studies
(e.g., [7]), no proof of this fact has been given before. We provide a simple proof of this theorem in
Appendix A.
Theorem 2.1
The bias b .XS / D EŒXS  S  of XS is maximal when 1 D    D k .
The same theorem applies to two-stage designs, where at an interim analysis, a single treatment is
selected and recruitment to this group (and the control) is continued up to a prespecified sample size.
This follows from the fact that, in such two-stage designs, the second-stage MLE (computed from the
second-stage data only) is unbiased, and hence the selection bias of the overall MLE, which is a weighted
mean of the first-stage and second-stage MLE, is solely driven by the bias of the first-stage MLE.
2.2. Shrinkage estimator of S for k > 4 treatments
Hwang [13] focused on multi-armed trials with k > 4 experimental treatments and proposed Lindley’s
estimator [14] for estimating the mean S of the treatment S with largest average. This gives
the estimator
QLS D OCCXS C .1  OCC/ NX; where OCC D max. OC ; 0/ with OC D 1 
.k  3/2
n
Pk
jD1.Xj  NX/2
: (1)
Lindley’s estimator shrinks the conventional MLE XS towards the overall sample mean NX DPk
iD1 Xi=k.
One can see by heuristic arguments that this estimator is reasonable. For 1 D    D k , the overall
mean NX is the most efficient estimator for S and nPkjD1.Xj  NX/2=2  2.k  1/ has its mode at
k  3. Therefore, OCC is likely to be close to 0 in which case shrinkage to NX is strong. If 1; : : : ; k are
far from each other, that is, maxi 6Dj ji  j j is large, then
Pk
jD1.Xj  NX/2 is likely to be large and OCC
is likely to be close to 1. As a consequence, QLS is close to XS , which is reasonable because the bias of
XS is small for large maxi 6Dj ji  j j.
Hwang considered the problem from an empirical Bayesian point of view and showed that QLS
uniformly improves XS within this framework. To this end, he assumed conjugate independent and
identically distributed (i.i.d.) normal priors i  N.; 2/ and that Xi j i  N.i ; 2=n/, i D 1; : : : ; k,
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for a known variance 2. These assumptions correspond to a random effects model for the replicates Xij
with treatment as a random factor and a known residual variance 2. The Bayes estimator for S is
QBS D E ŒS jX1; : : : ; Xk D CXS C.1C/ ; where C D n2=.2Cn2/ D 12=.2Cn2/ :
(2)
The estimator QBS is an unbiased predictor for S in the sense that
E.QBS / DEfE.S jX1; : : : ; Xk/g D E.S /
D
Z 1
1
  
Z 1
1
 
kX
iD1
i P .S D i/
!


1  
2

  

k  
2

d1    dk;
where the expectations are with respect to the data and i.i.d. normal priors as indicated for E.S /. It
coincides with the best linear unbiased predictor (BLUP) for the random effects model and is known to
have minimal Bayes risk
R; .Q
B
S / D
Z 1
1
  
Z 1
1
E
n
QBS  S
2o


1  
2

  

k  
2

d1    dk :
The Bayes risk is the integral of MSE .QBS / with regard to the normal prior distribution for 1; : : : ; k .
Replacing in (2) the unknown  with its mean unbiased estimator NX and the unknown C with the pos-
itive part of OC D 1  .k  3/2=
h
n
Pk
jD1.Xj  NX/2
i
( OC can be shown to be mean unbiased for C)
leads to Lindley’s estimator (1). Hwang verified the following domination result.
Theorem 2.2
If k > 4, then QLS has uniformly smaller Bayes risk than XS , that is, R; .QLS / 6 R; .XS / for all i.i.d.
N.; 2/-distributed priors.
We finally comment on the relationship between this and Brown’s [13] admissibility result for the
MLE. Brown follows the frequentist’s point of view and considers the MSE for each parameter configu-
ration asking for an estimator that dominates the MLE uniformly with regard to all mean configurations.
Hwang takes the Bayesian’s point of view and considers the Bayes risk where the MSE is averaged over
the parameter space with regard to i.i.d. normal priors. Such averaging allows him to find an estimator
(namely, Lindley’s estimator) that outperforms the MLE with regard to the Bayes risk for all i.i.d. normal
priors, even though according to Brown, no estimator can outperform the MLE with respect to the MSE
for all parameter configurations.
2.3. Extensions
Hwang considered several extensions of the aforementioned domination result. One extension is for
the case of unknown variance 2. He showed that the domination theorem 2.2 remains true if we
replace in QLS the unknown 
2 by the estimator O2 D PkiD1PnjD1.Xij  Xi /2=fk.n  1/ C 2g.
The latter estimator is biased but more efficient (in terms of MSE) than the unbiased estimator
s2 DPkiD1PnjD1.Xij  Xi /2=fk.n  1/g.
Hwang also considered estimation of all ordered group means .1/; : : : ; .k/ where the ordering is
according to the MLEs, that is, X.1/ < X.2/ <    < X.k/. He showed the same domination result for
Lindley’s estimator QL
.i/
of .i/ for all i 6 k, where QL.i/ is defined as in (1) but with S equal to the
index of the group .i/ from the i th smallest MLE. This leads to the question for which selection rules
Theorem 2.2 remains true. We investigated Hwang’s proof and found that it applies to any selection rule
S D S

.X1  NX/=
p
V ; : : : ; .Xk  NX/=
p
V ;W

, where V D PkjD1.Xj  NX/2 and W is a random
vector that is stochastically independent from the groups means and does not influence the choice of
the prior distribution. Examples for W are external data and/or an estimator of the common unknown
variance 2. We provide the proof of this result in Appendix A.
An interesting application of the latter extension are cases where the selection depends on a multi-
variate normal outcome with one component representing the primary efficacy variable X and the other
components the secondary or safety variables. Because the multivariate normal outcome vector can be
decomposed into the vector of the primary variable and the projection of the secondary and safety vari-
ables into the orthogonal complement of the primary outcome vector, which is independent from the
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primary outcome variable, our extension covers selection rules that depend on the standardized means
.Xi  NX/=
p
V and the secondary and safety endpoints. One particularly interesting case is where the
selection depends on the ordering of the means and the secondary and safety variables. This covers
the case of sometimes selecting the second (or even third) best-performing treatment (instead of the
best-performing one) on the basis of the secondary and safety endpoints.
3. Point estimation in two-stage designs with treatment selection
We consider now two-stage designs with treatment selection at the interim analysis. To this end,
we let X1; : : : ; Xk be the first-stage sample means, based on a sample size of n1 subjects per
group (equal for all treatments). We assume that S is the index of the best-performing treat-
ment at the interim analysis, that is, XS D max.X1; : : : ; Xk/, or any other selection rule S D
S

.X1  NX/=
p
V ; : : : ; .Xk  NX/=
p
V ;W

where W is independent from X1; : : : ; Xk . Suppose fur-
ther that n2 subjects are recruited in the selected treatment arm in the second stage. Let YS be the
second-stage sample mean for the selected treatment. The overall MLE at the end of the two-stage
design can be written as QMLES D tXS C .1  t /YS , where t D n1=.n1 C n2/.
3.1. Extension of Lindley’s estimator
Our goal is to extend Hwang’s domination result [13] to two-stage designs with treatment selection
whereby we focus on the case of selecting a single experimental treatment at the interim analysis. We
define for k > 4 the following two-stage version of Lindley’s estimator
QLS D tQL;1S C .1  t /YS ; (3)
where QL;1S is Lindley’s estimator (1) from the first-stage data. Because the second stage contin-
ues with only one experimental treatment, there is no need to adjust the second-stage MLE. We
show in Appendix A that Hwang’s domination result also applies to the two-stage version (3) of
Lindley’s estimator.
Theorem 3.1
If k > 4, then Lindley’s two-stage estimator (3) has uniformly smaller Bayes risk than QMLES , that is,
R; .Q
L
S / 6 R; .QMLES / for all N.; 2/-distributed priors.
It can be seen from the proof in Appendix A that the theorem applies whenever the first-stage esti-
mator QL;1S has uniformly smaller Bayes risk than the first-stage mean XS . Hence, the result covers all
extensions mentioned in Section 2.3.
3.2. The case k D 2; 3
Lindley’s estimator is defined only for k > 4, whereas the Bayes estimator (2) is defined and optimal
with regard to the Bayes risk for all k > 2. The restriction of Lindley’s estimator to k > 4 is caused by
the use of the mean unbiased estimator OC for C , which is defined only for k > 4. It appears natural to
consider the Bayes estimator with another estimator for C when k D 2; 3. To this end, we suggest to
adopt the random effects model point of view and use for the first-stage estimator the standard estimator
of the BLUP, which is defined for all k > 2 and equals Lindley’s estimator (1) with k  3 replaced by
k1 (e.g., [17]). More precisely, we consider replacing Lindley’s estimator QL;1S in (3) by the estimated
BLUP from the random effects model for the first-stage data. No domination result is known for this type
of estimator; however, simulation results shown in the next section indicate that this estimator performs
well compared with the MLE and previously proposed bias-adjusted estimators.
4. Simulation results
We have performed an extensive simulation study to investigate the performance of our two-stage ver-
sion (3) of Lindley’s estimator and of the estimated BLUP for k D 2; 3 in comparison with the MLE
and the two different mean bias-adjusted estimators of Cohen and Sackrowitz [8] and Stallard and
Todd [10]. For completeness, we start with a brief description of the two mean bias-adjusted estimators.
We then present the simulation results.
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4.1. Cohen and Sackrowitz’s two-stage estimator of S
Cohen and Sacrowitz [8] proposed a two-stage estimator of the mean of the best-performing treatment
that is conditionally unbiased given the order statistics of the first-stage sample means and has uni-
formly minimum variance among all such conditionally unbiased estimators. Of course, a conditionally
unbiased estimator is also unconditionally unbiased. One interesting feature of this estimator is that it
depends on the first-stage data only through the first two order statistics of the first-stage sample means.
Therefore, for k > 3, the method does not utilize all first-stage data. Hence, there is a potential for an
improvement (in terms of MSE) by estimators that utilize all interim data. Our two-stage version of
Lindley’s estimator and the BLUP utilize all interim data.
Bowden and Glimm [11] extended Cohen and Sackrowitz’s work to unequal group variances and
selecting not only the most-promising but also j th most-promising treatment for j 6 k.
4.2. Stallard and Todd’s estimator of S
Stallard and Todd [10] considered the mean bias of the MLEs conditional on the selection of treatment
S , that is, b .i IS/ D E .QMLEi jS/ for i D 1; : : : ; k, and derived numerical expressions for these con-
ditional selection biases. They suggested to subtract the selection bias b .i IS/ from each MLE QMLEi .
Because bias depends on the unknown  D .1; : : : ; k/, only an estimator of the conditional biases
can be subtracted. Stallard and Todd proposed an iterative approach similar to the iterative scheme in
Whitehead [18]. Their method is computationally intensive as it requires numerical integration within
each iteration. It can also happen that the iterative approach diverges in which case no estimator is
provided. We have observed such divergence problems in several realistic scenarios.
4.3. Simulation input
We have considered two-stage designs in which the total sample size for the selected treatment is fixed to
N D 100 subjects and the standard deviation to  D 3:155 such that a difference in means of 1:25 could
be detected in a two-treatment comparison with a power of 80%. We have varied the information fraction
at the interim analysis by considering a range of first-stage sample sizes from 10 to 100 in steps of 10
subjects. For each scenario, we have run 106 iterations for all methods except Stallard and Todd’s for
which we have run 104 iterations because of its extensive numerical calculations. We have considered the
procedures of selecting the best-performing and the second best-performing treatments at interim anal-
ysis for all methods except Stallard and Todd’s, which only works when selecting the best-performing
treatment. The results of the simulation study are given in units of the total standard error, that is, in
terms of b.QS /=
q
2
N
D EŒQ  S =
q
2
N
and
p
MSE.QS /=
q
2
N
DpEŒ.QS  S /2=q2N .
4.4. Selection of the best-performing treatment
On the top row of Figure 1, we present a scenario with k D 6 equally effective treatments (1 D    D
k D 0). The graphs show the information fraction on the x-axis. The y-axis gives the standardized
selection bias on the left graph and the square root of the standardized MSE on the right graph. We see
that Lindley’s estimator considerably reduces the selection bias as well as the MSE compared with the
MLE. Cohen and Sackrowitz’s estimator perfectly corrects for the bias but at the price of a substan-
tial increase in the MSE. The curves end at t D 0:9, because the method requires an interim analysis.
Stallard and Todd’s method overcorrects the bias, which leads to an inflation of the MSE compared with
the MLE.
On the middle row of Figure 1, we present a scenario in which there is a linear relationship between
the effects of the treatments; that is, i D 0:25  .i  1/, for i D 1; : : : ; 6. We observe that the selection
bias of the MLE is less problematic than in the previous scenario, but it is still present. Lindley’s esti-
mator still has a reduced bias and a slightly reduced MSE compared with the MLE. The performance
of Cohen and Sackrowitz’s method in this scenario is similar to that of the previous one; the method
perfectly corrects for the bias and has an inflated MSE although this inflation is less pronounced. The
performance of Stallard and Todd’s method in this scenario is also similar to that of the previous one.
On the bottom row of Figure 1, we present a scenario in which only one treatment is effective;
1 D    D 5 D 0 and 6 D 1:25. Lindley’s estimator overcorrects the bias in this case but still
performs reasonably well with respect to the MSE compared with the MLE. Lindley’s estimator is at
least conservative with regard to bias.
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Figure 1. Selecting the best-performing treatment among k D 6 treatments at the interim analysis. MLE,
maximum-likelihood estimator; MSE, mean squared error; C & S, Cohen and Sackrowitz; S & T, Stallard
and Todd.
Stallard and Todd’s method had severe divergence problems when the interim analysis is performed
late. The divergence rates were up to 5% when the interim analysis is performed at an information frac-
tion of t D 0:8, and it was between 20% and 30% when the interim analysis is performed at t D 0:9.
Divergence problems have also been observed with low rates for earlier interim analyses. The simulation
results shown for this method are conditional on convergence.
We have performed similar simulations assuming  is unknown and have estimated it in QL;1S by
the estimator O mentioned in Section 2.3. We found essentially no difference between the known and
unknown variance case.
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We finally performed a similar simulation study for k D 2; 3 experimental treatments, replacing
Lindley’s estimator with the two-stage version of the estimated BLUP from the corresponding random
effects model. Figure 2 shows the results for the case k D 3. One can see from the figure that the
estimated BLUP performs similarly well as Lindley’s estimator, improving the MLE and the two bias-
adjusted estimators in terms of MSE, although no domination result is available for this estimator. We
obtain similar results for k D 2.
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Figure 2. Selecting the best-performing treatment among k D 3 treatments at the interim analysis. MLE,
maximum-likelihood estimator; MSE, mean squared error; BLUP, best linear unbiased predictor; C & S, Cohen
and Sackrowitz; S & T, Stallard and Todd.
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4.5. Selection of the second best-performing treatment
In this section, we present the same three scenarios as in the previous section with k D 6 treatments but
we select the second best-performing treatment instead. (We performed similar simulations for k D 3
and found essentially the same results.)
Figure 3 presents standardized bias and square root of standardized MSE for the maximum-likelihood,
Lindley’s and Bowden and Glimm’s estimators. We see that Lindley’s estimator reduces the selection
bias as well as the MSE compared with the MLE. Bowden and Glimm’s estimator perfectly corrects for
the bias and also at the price of a dramatic increase in the MSE.
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Figure 3. Selecting the second best-performing treatment among k D 6 treatments at the interim analysis. MLE,
maximum-likelihood estimator; MSE, mean squared error; B & G, Bowden and Glimm.
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For the scenario with only one effective treatment, at the bottom line of Figure 3, we see that the MLE
exhibits a large bias. This is because most of the time the best-performing treatment will be the effective
one and the second best-performing treatment will be the one that shows the largest effect among the
five noneffective treatments. Lindley’s estimator reduces the bias as well as the MSE compared with the
MLE, and both methods clearly outperform Bowden and Glimm’s method with respect to the MSE.
The relatively large bias of Lindley’s estimator in the last scenario has motivated us to consider a mod-
ification of this estimator for the case when the second best treatment is selected. In this case, we could
adopt a conservative strategy in which we ignore the mean of the best-performing treatment. This means
to compute Lindley’s first-stage estimator only with the second largest and all smaller group means.
Of course, we suggest to apply such modification only when selecting the second-best treatment. More
generally, when selecting the j th best treatment at interim, the shrinkage estimator could be constructed
from this and smaller interim means. This will always lead to an estimator that is more conservative than
Lindley’s estimator and the MLE.
We have run simulations for this modification when always selecting the second-best treatment.
Figure 4 shows the result for the scenario where only one treatment is effective. In this scenario, the
unmodified Lindley’s estimator performed not so well. One can see that the modified estimator performs
much better with regard to bias and MSE. We observed only small differences in bias and MSE between
the modified and the unmodified Lindley’s estimator for the other mean patterns.
4.6. Additional simulation results
We considered more scenarios than the ones presented in the previous subsections. Our simulation study
included, for instance, the same mean patterns as presented previously but with an increased variance
such that the power of the two-group comparison between the most effective and control groups was
only 60%. We also considered step functions with two and three plateaus, several scenarios where one
treatment was clearly more effective than the others and patterns with an exponential increase of the
treatment effect. We furthermore performed simulations with only two experimental treatments. We
obtained the same results in all scenarios: the shrinkage estimator outperformed all other methods in
terms of the MSE, except in the case where one treatment was clearly more effective than the others,
in which case, the MSE of the shrinkage estimator was comparable with that of the other methods. The
shrinkage estimator also showed a substantial reduction of bias compared with the MLE. In the case
where one treatment was clearly more effective than the others, Lindley’s estimator overcorrected the
bias. Given that the results are invariant with respect to permutations of the treatment effects, we have
covered a broad range of realistic scenarios.
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Figure 4. Selecting the second best-performing treatment among k D 6 treatments at the interim analy-
sis when the shrinkage estimate is computed only from the second best and all worse treatments. MLE,
maximum-likelihood estimator; MSE, mean squared error; B & G, Bowden and Glimm.
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5. Discussion
On the basis of previous work on shrinkage estimation in single-stage multi-armed trials, we have consid-
ered shrinkage estimation in adaptive two-stage designs with selection of a single experimental treatment
arm at the interim analysis. We have particularly extended the work of Hwang [13] who showed that
Lindley’s estimator [14] dominates the MLE in terms of Bayes risk within an empirical Bayesian frame-
work with independent normal priors. We have shown that the same domination result applies to a
natural extension of Lindley’s estimator to the two-stage design. The two-stage version of Lindley’s esti-
mator is the weighted mean of the first-stage Lindley’s estimator and the single second-stage MLE of
the selected treatment. Lindley’s estimator applies to designs that start with at least four experimental
treatments. For designs with less treatments, we considered using the standard estimator of the BLUP of
the corresponding random effects model for the first-stage estimator.
We have investigated by simulation studies the performance of the two-stage version of Lindley’s
estimator and the estimated BLUP and have found favorable properties of these estimators in compari-
son with the MLE and the bias-adjusted estimators of Cohen and Sackrowitz [8] and Stallard and Todd
[10]. Although Cohen and Sackrowitz’s estimator perfectly removes the selection bias, it has increased
variance in a way that the MSE is generally larger than for the MLE. Stallard and Todd’s estimator was
found to have the tendency for an overcorrection of bias, at least in the two-stage setting, and it is also
in general inferior to the MLE and shrinkage estimators in terms of MSE. The two-stage shrinkage esti-
mators did, on the one hand, reduce selection bias of the MLE substantially (although not removing it
completely) and, on the other hand, improved or was equivalent to the MLE in terms of MSE. Because
we believe that MSE is more appropriate as measure of precision than the bias itself, we suggest using
shrinkage estimators to deal with the problem of selection bias.
In practice, we not only report the estimate but also a measure of precision of the estimate such as
its standard error. This is possible only if the treatment selection process follows a known prespecified
rule because, otherwise, the distribution of the estimate remains unknown. This applies to any treatment
effect estimate. When the rule is known, then the variance of the shrinkage estimate can be determined,
for instance, by parametric or nonparametric bootstrapping. We suggest to report the MSE instead of
the variance, because the MSE also accounts for the bias and hence is a more conservative measure for
the precision of the estimate. Reporting the variance would lead to an overestimation of the precision.
Another related topic is the construction of simultaneous confidence intervals. Simultaneous confidence
intervals should be consistent with the test decision of the multiple hypothesis test for the superiority
or noninferiority hypotheses of primary interest. Consistency means that there should be no contradic-
tion between the parameters excluded by the confidence intervals and those excluded by the hypothesis
tests. Authors have suggested efficient hypothesis testing methods for designs with treatments selection
(e.g., [3–6]), and any simultaneous confidence interval should be discussed in comparison with such test
procedures (e.g., [5]).
We did not directly address other important extensions of our work. One important extension is to
designs with a control group where the treatment effect is measured in terms of the mean difference
between the selected experimental treatment and control group. If the control group is continued with
the selected treatment to the second stage, then we can subtract the MLE of the control group from the
shrinkage estimator to obtain an estimator that performs similarly well in terms of bias and MSE. The
reason why we can expect the same favorable properties is that the MLE of the control group is mean
unbiased (and hence, all bias is driven by the estimator for the treatment group) and the MSE of the
difference between treatment and control group is just the sum of the MSEs of the estimators for the
treatment and control group. Hence, the domination result applies, and simulation results will be similar
for designs with control group (see [7] for similar arguments).
Another important extension is to designs where, in addition to treatment selection, the second-stage
sample size is assessed at the interim analysis. One important case is covered by our exposition, namely,
the case where the sample sizes of the dropped treatment arms are reshuffled to the selected treatment
and control arm in equal (or some other prespecified) parts. In this case, the second-stage sample sizes
will always be the same and hence are as if they where fixed in advance. More general sample size
adaptations rules, for example, based on conditional power, are not covered by our work and require
additional research. A particularly difficult but interesting problem is how far the domination result can
be extended to designs including data-driven sample size adaptations.
Another important extension that is covered only partly by our research are designs where more than
a single treatment is selected at the interim analysis. If we are concerned only with the bias caused by the
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interim selection process, then we can use the two-stage shrinkage estimators considered here for each
of the treatments selected at the interim analysis. However, if we wish to account also for the bias caused
by the second selection process at the end of the trial (where we select one of the multiple treatments
considered until the end of the trial), then the selection bias problem becomes much more difficult. In
this case, a natural approach would be to use the weighted mean of first-stage and second-stage shrink-
age estimators. However, we have not been able to prove a domination theorem for such an estimator.
This is another interesting open question for future research.
Appendix A
Proof of Theorem 2.2
Because the joint distribution of fX1  1; : : : ; Xk  kg is independent of the true mean vec-
tor  D .1; : : : ; k/, also C D E Œmax.X1  1; : : : ; Xk  k/ is independent of  . Because
max.X1  1; : : : ; Xk  k/ > XS  S , we obtain C > E ŒXS  S  for any  and any selection
rule S . Therefore, C is an absolute upper bound for the selection bias that is independent of the true
 as well as of the selection rule. Finally, if 1 D 2 D    D k D  and XS D max.X1; : : : ; Xk/,
we obtain that max.X1  ; : : : ; Xk  / D max.X1; : : : ; Xk/   D XS  S , which implies that
C D EŒXS  S . Hence, b .XS / attains the absolute upper bound C if 1 D 2 D    D k D  and
XS D max.X1; : : : ; Xk/. 
Proof of Theorem 3.1
Observe that
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because E; ŒYS  S j X1; : : : ; Xk; W  D 0. Therefore,
E
h
QL  S
2iD t2R; QL;1S C .1  t /2E; ˚.YS  S /2
 :
Similarly, E

.QN  S /2
 D t2R; .XS / C .1  t /2E; ˚.YS  S /2
. The domination result in the
two-stage setting is a direct consequence of Theorem 2.2, which implies that for k > 4, R; .QL;1S / 6
R; .XS / for all  and  . 
Hwang’s domination result with more general selection rules
Let S 2 f1; : : : ; kg, k > 4, be the index of the selected treatment and suppose that S D
h.Z1; : : : ; Zk; W /, where Zi D .Xi  NX/=
p
V , for i D 1; : : : ; k, NX D PkjD1 Xj =k, V D PkjD1
.Xj  NX/2 and W is independent from the group mean vector X D .X1; : : : ; Xk/ for any given mean
vector  . Because W is independent from X and the a priori distribution does not depend on W , we can
assume that W is a fixed (nonrandom) vector and consider S as function of the Zi only. We present the
proof of Theorem 2.2 for such selection rules. The proof follows the lines of the proof in Hwang [13].
Before we prove the theorem, we note that, for any estimator ı D ı.X/ of S , the posterior risk,
namely, the risk conditional on X , is E
˚fS  ı.X/g2 jX
 D fı.X/  QBS g2 C 22=.2 C n2/.
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Hence, the Bayes risk of ı is R.ı/ D E
h˚
ı.X/  QBS

2i C 22=.2 C n2/. We now consider
estimators of the form ı.X/ D g.V /.XS  NX/ C NX . From simple algebra, we obtain
ı.X/  QBS D Œg.V /  C  .XS  NX/ C .1  C/. NX  / : (A1)
Because Xi  NX , 1 6 i 6 k and NX are stochastically independent and S is a function of Xi  NX ,
1 6 i 6 k, it follows that also XS  NX and NX are stochastically independent. Therefore, the first term on
the right-hand side of Equation (A1) is independent of the second term, and hence
E
h˚
ı.X/  QBS

2iD E hfg.V /  C g2 XS  NX2iC .1  C/ 2=.nk/ : (A2)
Now, E
˚
.XS  NX/2 jV

 D E ˚Z2S jV 
 V . Because the distribution of Z2S D Z2h.Z1;:::;Zk/ is indepen-
dent from 2, and V is a complete sufficient statistic for 2 (with regard to the group means X1; : : : ; Xk),
we obtain from Basu’s theorem that Z2S and V are independent. Hence,
E
˚
.XS  NX/2 jV

D cSV (A3)
for some constant cS > 0 that does not depend on , 2, or 2. Using conditional arguments,
Equations (A2) and (A3) and the identity 22=.2 C n2/ D .1  C/2, we obtain
R.ı/ D cSE
fg.V /  C g2V C .1  C/ ˚2=.nk/ C 2
 : (A4)
We consider now the estimator ı.a/ D f1  a2=.nV /g XS  NXC NX for arbitrary a > 0. Note that
ı.0/ D XS , and ı.k3/ is close to Lindley’s estimator but with OC instead of OCC. To complete the proof,
we show that (i) QLS has smaller Bayes risk than ı.k  3/ and (ii) that ı.k  3/ has smaller Bayes risk
than ı.0/. To show (i), note that by Equation (A4), we have that R.QLS / < Rfı.k  3/g if and only if
E
(
1  .k  3/
2
nV

C
 C
2
V
)
< E
(
1  .k  3/
2
nV

 C
2
V
)
and that the last inequality is obvious. For (ii), note that by (A4), we obtain Rfı.a/g D cSEŒf1 
C  a2=.nV /g2V  C .1  C/ f2=.nk/ C 2g. From the identities E.V / D .2=n C 2/.k  1/ and
E.1=V / D f.2=n C 2/.k  3/g1 and direct evaluations, we get that EŒf1  C  a2=.nV /g2V  D
2.1C/ k  1  2a C a2=.k  3/, which is uniquely minimized for a D k 3. This establishes (ii),
completing the proof.
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Adaptive seamless designs with interim
treatment selection: a case study
in oncology
Máximo Carreras,a*† Georg Gutjahrb and Werner Brannathb
The planning of an oncology clinical trial with a seamless phase II/III adaptive design is discussed. Two regimens
of an experimental treatment are compared to a control at an interim analysis, and the most-promising regimen
is selected to continue, together with control, until the end of the study. Because the primary endpoint is expected
to be immature at the interim regimen selection analysis, designs that incorporate primary as well as surrogate
endpoints in the regimen selection process are considered. The final testing of efficacy at the end of the study
comparing the selected regimen to the control with respect to the primary endpoint uses all relevant data collected
both before and after the regimen selection analysis. Several approaches for testing the primary hypothesis are
assessed with regard to power and type I error rate. Because the operating characteristics of these designs depend
on the specific regimen selection rules considered, benchmark scenarios are proposed in which a perfect surrogate
and no surrogate is used at the regimen selection analysis. The operating characteristics of these benchmark
scenarios provide a range where those of the actual study design are expected to lie. A discussion on family-wise
error rate control for testing primary and key secondary endpoints as well as an assessment of bias in the final
treatment effect estimate for the selected regimen are also presented. Copyright © 2015 JohnWiley & Sons, Ltd.
Keywords: adaptive seamless designs; treatment selection; surrogate endpoints; family wise error rate; confi-
dence intervals; selection bias
1. Introduction
Adaptive seamless designs with interim treatment selection have been considered extensively in the lit-
erature; see Bauer & Brannath [1] and Bretz et al. [2] for comprehensive reviews. Hypothesis testing
methods have been developed that allow the treatment to be selected at the interim analysis, incorporating
all available information, including information external to the study, while controlling the overall mul-
tiple type I error rate at a prespecified level 𝛼 [3–6]. Schäfer and Müller [7] extended the adaptive design
methodology to survival data by using the conditional error approach [8] and applying the independent
increments structure of the log-rank statistics. But Bauer and Posch [9] pointed out that caution must
be exercised when applying these flexible designs: in the particular setting of a two-stage design with
treatment selection after the first stage, it means that stage 2 p-values for the comparison of the selected
treatments with the control at the end of the study cannot be influenced by surrogate information of stage
1 patients who are at risk at the interim treatment selection analysis. Therefore, the standard testing pro-
cedure of Schäfer and Müller [7] that combines stage-wise p-values computed from increments of the
log-rank statistic (see also Wassmer [10]) may not protect the type I error rate unless treatment selection
is based only on the score statistics of the primary endpoint, which is unrealistic in practice. In the con-
text of enrichment designs, Jenkins et al. [11] proposed a testing procedure that preserves type I error
rate while allowing all information collected until the interim analysis to be used for treatment selection.
König et al. [12] suggested a testing procedure based on a modification of the classical Dunnett [13] test,
which guarantees strict control of type I error rate without imposing any restrictions on the information
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that can be used at the interim analysis for treatment selection purposes. The method by König et al. [12]
has, however, not been developed for time-to-event data so far. Di Scala and Glimm [14] extended the
classical Dunnett [13] test to survival data for adaptive seamless designs with interim treatment selection.
In this article, the planning of an oncology clinical study with an adaptive seamless phase II/III design
is discussed. Two regimens of an experimental treatment are compared to a control at an interim analysis,
and the most-promising regimen is selected to continue, together with control, until the end of the study.
Because the study’s primary endpoint will be immature at the regimen selection analysis, it is of interest
to investigate whether the incorporation of surrogate information can help improve the regimen selection
process and thus the study’s probability of success. To this end, designs are considered, which include
the primary as well as surrogate endpoints in the regimen selection analysis. At the end of the study,
testing of efficacy is carried out to compare the selected regimen to the control with respect to the primary
endpoint, utilizing all relevant data collected both before and after the interim analysis.
The aforementioned three approaches [7, 11, 12] are assessed with regard to power and type I error
rate for testing the primary null hypothesis comparing the selected regimen to the control at the end of
the study. Because the operating characteristics of these designs depend on the specific regimen selection
rules considered, on the correlation between primary and surrogate endpoints and on the true standardized
mean difference of the surrogate endpoint(s), benchmark scenarios are proposed in which a ‘perfect
surrogate’ and no surrogate is used at the regimen selection analysis. The operating characteristics of
these benchmark scenarios provide a range where those of the actual study design are expected to lie.
This article is organized as follows. In Section 2, the case study is introduced. Section 3 discusses
hypothesis testing methods for the primary endpoint. Section 4 presents the treatment selection rules that
are used in our simulation study, which are a simplification of the actual selection rules used in the case
study. A discussion on family-wise error rate (FWER) control for testing primary and key secondary end-
points is presented in Section 5. In Section 5, estimation of treatment effect for the selected regimen at
the end of the study is considered, including an assessment of bias as well as the construction of confi-
dence intervals. In Section 7, the assumptions and results of a thorough simulation study are presented.
Finally, Section 8 presents our concluding remarks.
2. The case study
The case study is an open label study that aims to evaluate the efficacy and safety of two dose regimens
of an experimental treatment as a single-agent targeted therapy compared to an active control in patients
with previously treated HER2-positive locally advanced or metastatic gastric cancer (MGC). The low-
dose regimen of the experimental treatment was shown to be effective in metastatic breast cancer (MBC).
But results of another study investigating a closely-related compound showed that drug exposure levels in
MGC could be up to 50% lower than those in MBC. Therefore, in order to mitigate the risk of insufficient
drug exposure with the low-dose regimen, the sponsor decided to also incorporate a high-dose regimen
in the study.
Several options were considered for the development program. A standard program with phases II
and III run in separate studies was considered to have too long timelines and was regarded as a moder-
ate business case for a fast-to-market product development. A three-arm phase III design with regimen
selection at the end of the study was deemed to carry regulatory and payer challenges (e.g., the high-
dose regimen could be more efficacious but could have a worse safety profile compared to the low-dose
regimen, leading to similar benefit/risk profiles. If both regimens were approved by regulatory authori-
ties, negotiations with payers about price of each regimen would be difficult). The seamless phase II/III
adaptive design with interim regimen selection analysis was considered to provide the best option for the
program in terms of timelines and probability of success. In this paper, we compare these three options
with respect to power.
Because the study’s primary endpoint, overall survival (OS), will be immature at the interim analysis
(only 50 deaths are expected across the three arms) and secondary efficacy endpoints such as progression-
free survival or objective response rate are not considered to be good surrogates for OS in this indication,
the regimen selection criteria incorporate drug exposure as an important decision driver. The regimen
selection analysis will be carried out after approximately 100 patients across all three arms have been
enrolled and followed for a minimum of 12 weeks, which should provide sufficient pharmacokinetics
data for decision making. An Independent Data Monitoring Committee (IDMC) will recommend one of
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the two experimental regimens based on all pharmacokinetics, safety, and efficacy data available at that
time. The IDMC is guided to select the high-dose regimen only when the following three conditions
are satisfied:
• Mean (cycle 1) area under the plasma drug concentration versus time curve (AUC) of the high-
dose regimen is at least 50% larger than that of the low-dose regimen (mean cycle 1 AUC for the
experimental arms is expected to be in the range of 200–350 days×𝜇g∕mL)
• Efficacy of the high-dose regimen is comparable or superior to that of the low-dose regimen
• High-dose regimen has an acceptable safety profile.
Otherwise, the IDMC is guided to select the (default) low-dose regimen. No early stopping for efficacy or
futility is allowed at the regimen selection analysis. The IDMC has the authority to recommend stopping
the study due to safety at any time during its course. Accrual will continue into all three treatment arms
until the regimen selection analysis has been completed.
The sample size requirements for the study have been obtained using computer simulations. A total
sample size of approximately 410 patients will be recruited into the study. A median OS of 9 months
in both experimental arms and of 6 months in the control arm are expected to be observed in the study.
Under the assumption of proportional hazards, this corresponds to a hazard ratio (HR) of 0.67 between
each experimental arm and the control.
3. Hypothesis testing for the primary endpoint
In order to avoid conflicting directional effects at the two stages of the study to combine into a single
final directional test decision, a one-sided hypothesis testing framework is adopted for OS. The null
hypotheses H0i ∶ 𝜃i ≥ 0; i = 1, 2, where 𝜃i is the log-HR for the parameter OS between the i-th experi-
mental treatment and the control, are considered.
In this section, we present the three testing procedures mentioned in the introduction. In order to do this,
the following test statistics Uij, i = 1, 2 and j = a, b, c, d are considered, where:
(a) Uia is the log-rank statistic to test H
0
i at the regimen selection analysis, defined as the difference
between the number of deaths observed in the i-th experimental arm and the number of deaths
expected under H0i at that time;
(b) Uib is the log-rank statistic to test H
0
i at the final analysis using stage 1 and stage 2 patients;
(c) Uic is the log-rank statistic to test H
0
i at the final analysis using only stage 1 patients;
(d) Uid is the log-rank statistic to test H
0
i at the final analysis using only stage 2 patients.
The statistics Uia,Uib,Uic, and Uid are computed using data from the regions depicted in Figure 1 for
treatment i and control. Let Vij be the variance of Uij and define Zij = Uij∕
√
Vij for all i, j. Let S = s
Figure 1. Graphical representation of the data used to compute the test statistics Uij, i = 1, 2, and j = a, b, c, d.
Uia is computed using data from the bottom left triangle in the figure for the i-th experimental treatment and
the control. Uib is computed using data from all three regions in the figure. Similar interpretations follow for
Uic and Uid.
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denote the index of the regimen selected at the regimen selection analysis and let Φ denote the standard
normal CDF.
3.1. Testing procedure 1 (follow-up-wise staging)
In this testing procedure, stage 1 p-values are calculated by pia = Φ
(
Zia
)
. Using the independent and
normally distributed increments structure of the log-rank statistic [10], the stage 2 p-value for the selected
treatment is calculated by ps(b−a) = Φ
(
Zs(b−a)
)
, where Zs(b−a) = (Usb − Usa)∕
√
Vsb − Vsa, incorporating
all OS data from stage 2 patients as well as from continued OS follow-up of stage 1 patients in the selected
treatment and the control.
In order to account for the multiplicity of the testing procedure, the closure principle [15] is used,
which requires the calculation of a p-value for the intersection null hypothesis H01 ∩ H
0
2 of no difference
in OS between both treatments and the control. Using Hochberg’s procedure [16], the stage 1 p-value for
testing H01 ∩ H
0
2 is calculated by pint,1 = min{2min(p1a, p2a),max(p1a, p2a)} (other methods such as that
of Dunnett and Tamhane [17] could also be used). The stage 2 p-value for testing H01 ∩ H
0
2 is defined as
pint,2 = ps(b−a) (note that this is a conservative p-value).
The inverse normal combination method [10] is used to combine stage 1 and stage 2 p-values. The
combined p-value for testing H0s is calculated by ps,comb = 1 − Φ(Zs,comb), where Zs,comb = w1Φ
−1(1 −
psa) +w2Φ−1(1− ps(b−a)). Similarly, the combined p-value for testing H01 ∩H
0
2 is calculated by pint,comb =
1 − Φ(Zint,comb), where Zint,comb = w1Φ−1(1 − pint,1) + w2Φ−1(1 − pint,2). Finally, H0s is rejected at the
end of the study if both ps,comb and pint,comb are smaller than 𝛼. The weights w1 and w2 are calculated by
w1 =
√
e1
e1+e2
and w2 =
√
e2
e1+e2
where e1 denotes the number of deaths expected to be observed from
stage 1 patients across the three arms at the regimen selection analysis and e2 denotes the number of deaths
expected to be observed from stage 1 and stage 2 patients in the selected arm and control after the regimen
selection analysis and until the final analysis. In this paper, e1 and e2 are estimated by simulations.
As originally pointed out by Bauer and Posch [9] and further discussed by Jenkins et al. [11] in the
specific setting of seamless phase II/III adaptive designs with hypothesis selection, the method described
in this section does not necessarily protect the type I error because surrogate information, such as drug
exposure, of stage 1 patients who are at risk at the interim analysis influences both the treatment selection
decision and the stage 2 p-value for the comparison of the selected treatment with the control at the end
of the study. In the simulations, we investigate how serious the type I error inflation can be in some
specific settings.
3.2. Testing procedure 2 (patient-wise staging)
In this alternative testing procedure, p-values are computed separately for patients recruited into stage
1 and those recruited into stage 2. In particular, after the regimen selection analysis, stage 1 patients
continue to be followed-up for survival and stage 1 p-values are computed by pic = Φ
(
Zic
)
; i = 1, 2.
The stage 2 p-value for the comparison of the selected experimental arm with the control is calculated
by psd = Φ
(
Zsd
)
. The stage 1 and stage 2 p-values for testing H01 ∩ H
0
2 are calculated, respectively,
by pint,1 = min{2min(p1c, p2c),max(p1c, p2c)} and pint,2 = psd. The combined p-value for testing H0s
is calculated by ps,comb = 1 − Φ(Zs,comb), where Zs,comb = w1Φ−1(1 − psc) + w2Φ−1(1 − psd). Sim-
ilarly, the combined p-value for testing H01 ∩ H
0
2 is calculated by pint,comb = 1 − Φ(Zint,comb), where
Zint,comb = w1Φ−1(1 − pint,1) + w2Φ−1(1 − pint,2). Finally, H0s is rejected at the end of the study if both
ps,comb and pint,comb are smaller than 𝛼. The weights w1 and w2 are calculated by w1 =
√
e1
e1+e2
and
w2 =
√
e2
e1+e2
where now e1 denotes the number of deaths expected to be observed among stage 1
patients across the three arms by the time of the final analysis and e2 denotes the number of deaths
expected to be observed among stage 2 patients by the time of final analysis. Again, e1 and e2 are
estimated by simulations.
As discussed in Jenkins et al. [11], in order to ensure independence of stage-wise p-values, the total
length of survival follow-up of stage 1 patients must be pre-specified. It is not necessary to specify it
before the study starts (as suggested by Jenkins et al.), but it must be specified before the regimen selection
analysis takes place. This gives the flexibility to adjust the total length of survival follow-up of stage 1
(and stage 2) patients based on observed overall recruitment patterns until the regimen selection analysis
as well as on a potentially updated sample size requirements for stage 2. This restriction on the total
length of survival follow-up of stage 1 patients does not allow to define the date of the final analysis in the
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standard way as the date when a certain total number of deaths among stage 1 and stage 2 patients have
been observed. We see four options for defining the date of final analysis (options 1 and 3 have already
been mentioned by Jenkins et al.):
(1) A pre-fixed calendar date.
(2) The date when a pre-fixed number of deaths has been observed among stage 1 patients.
(3) The latest of the dates when pre-fixed numbers of deaths have been observed, respectively, among
stage 1 patients and stage 2 patients (separate stage-wise final analyses).
(4) The date when a pre-fixed number of deaths have been observed among patients in the selected
experimental arm and the control across both stages.
In this article, ‘pre-fixed’ (‘pre-specified’) means fixed (specified) before the interim analysis. Options
(1) and (4) require that the recruitment rate after the regimen selection analysis is not influenced by
the interim results; for example, under option (1), if interim results for the experimental treatments are
good, artificially slowing down the recruitment after the interim analysis will make the evidence from the
additional patients more immature and therefore less likely to influence the good interim results by the
fixed calendar date of the final analysis (similar arguments can be made for option (4). Recruitment rate
may be influenced by interim results in options (2) and (3) without affecting the type I error. Options (1)
and (2) have the problem that the total number of deaths, and consequently the power of the study, cannot
be controlled by the study team. Option (3) has the problem that, if the date when the pre-fixed number of
deaths among stage 1 patients is observed occurs before the corresponding date for stage 2 patients, any
death occurring among stage 1 patients in between the two dates cannot be used in the final analysis. On
the other hand, if the date when the pre-fixed number of deaths among stage 2 patients is observed occurs
before the corresponding date for stage 1 patients, all deaths occurring among stage 2 patients in between
the two dates can be used in the final analysis without compromising the type I error. The main advantage
of option (4) is that the study team has more control over power compared to options (1) and (2), because
we can guarantee enough power for the comparison of the selected treatment with the control.
3.3. Testing procedure 3 (conservative Dunnett test)
The testing procedure presented in this section is a modification of the conventional Dunnett [13] test
for the comparison of several treatments with a control as suggested in the introduction of König et al.
[12]. In this testing procedure, the final p-value for the comparison of the selected treatment with the
control is calculated as ps,fn = 1 − Φ̃𝜌
(
−Zsb,−Zsb
)
, where Φ̃𝜌 denotes the CDF of the bivariate normal
distribution with mean (0, 0)′ and variance covariance matrix
[
1 𝜌
𝜌 1
]
. The correlation 𝜌 is computed using
the corrected formulas in Section 3 of Di Scala and Glimm [14] paper under the assumption of the global
null hypothesis, which is the same as the estimated correlation that would be obtained under the situation
of normally distributed data. In the simulations presented in this paper, we assume a 1:1:1 randomization
ratio and therefore 𝜌 = 1∕2.
This testing procedure is basically the classical Dunnett test for the comparison of two treatments
against a control where the z-statistic for the deselected treatment is set to +∞. As mentioned by König
et al. [12], this procedure protects the type I error rate because the missing test statistic is imputed in a
strictly conservative way. It was also mentioned in that paper that the only possible adaptation with this
method is treatment selection.
The date of the final analysis can be defined as a pre-fixed calendar date or as a pre-fixed total number
of deaths to be observed in the selected experimental arm and the control. Both options again require the
recruitment rate after the regimen selection analysis not to be driven by interim results.
4. Treatment selection
When treatment selection is based on OS, we consider an obvious selection rule; select the treatment with
the largest OS effect observed at the interim analysis. When the treatment selection is based on exposure,
we consider the following selection rule: if the mean exposure in the high-dose regimen observed at the
interim analysis is at least 50% larger than that in the low-dose regimen, select the high-dose regimen.
Otherwise, select the low-dose regimen.
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The latter treatment selection rule is a simplified version of the actual rule used in the study. As the
low-dose regimen was the standard regimen in MBC, the team considered that there was no justification
in using the high-dose regimen inMGC unless exposure levels achieved with the high-dose regimen were
considerably higher than those achieved with the low-dose regimen.
4.1. Perfect surrogate approach
We consider a hypothetical situation in which drug exposure is a ‘perfect surrogate’; that is, a surrogate
endpoint that can perfectly predict survival time at the end of the study [9]. This can be achieved in the
simulations by considering the treatment selection rule that selects at the interim analysis the treatment
with the largest OS effect (smallest HR) observed at the final analysis, assuming that both treatment
groups would be continued until the end of the study. Note that the selection rule based on this ‘perfect
surrogate’ is not the same as a rule based on a surrogate endpoint, which is perfectly correlated to the main
endpoint: given the simulation model presented in Section 7.1, the latter rule selects at interim analysis
the treatment with the largest mean of a specific transformation of the survival times. As we show in
Section 7.3, the ‘perfect surrogate’ scenario provides an upper bound for type I error but not necessarily
for the power. In the simulations, we also consider scenarios where the primary and surrogate endpoints
have different degrees of correlation.
5. Testing primary and main secondary endpoints
Even though the primary endpoint of the study is OS, which is the only clinically relevant endpoint in
this indication, secondary efficacy endpoints such as progression-free survival or objective response rate
can help characterize the efficacy profile of the experimental treatment and results of analyses of these
secondary endpoints may be included in the product label.
Let H11 and H12 be the primary null hypotheses for regimens 1 and 2, and let H21 and H22 be the
corresponding secondary null hypotheses. We want to select one of the two regimens by a data-dependent
selection rule, test the primary hypothesis for the selected regimen, and then also test the secondary
hypothesis for the selected regimen only when the primary hypothesis has been rejected. The FWER
for the family  = {H11,H12,H21,H22} is the probability of rejecting at least one true hypothesis in 
under any configuration of true and false hypotheses in  . Because the actual regimen selection rule of
the study is unknown, the FWER must be controlled at level 𝛼 under any regimen selection rule.
As testing procedure 1 described in Section 3.1 does not control the FWER for the sub-family 1 =
{H11,H12} of primary hypotheses, there is no point to extend this procedure to testing the family  of
primary and secondary hypotheses. Testing procedure 2 described in Section 3.2 controls the FWER for
1 but it does not for family as the example in Appendix A shows (assuming that the primary hypothesis
is tested at full level 𝛼).
Define Dunnett’s critical value c1 for the primary hypotheses so that PH11∩H12(min{T11,T12} ≤ c1) = 𝛼,
where Tij denotes the test statistic to test Hij and Tij is assumed to be standard normally distributed under
Hij; i, j = 1, 2. Set 𝛼1 = Φ(c1) and 𝛼2 = 𝛼 − 𝛼1, with an associated critical value c2 = Φ−1(𝛼2). In
Appendix B, we demonstrate that FWER is controlled for the family  with the conservative Dunnett
procedure presented in Section 3.3 when testing the primary hypothesis at level 𝛼 and the secondary
hypothesis at level 𝛼2.
Dimitrienko et al. [18] propose a similar parallel gatekeeping [19] procedure based on the Dunnett test
[13], which accounts for the inherent correlation among all four test statistics. The method by Dmitrienko
et al. [18] cannot be applied directly to our situation. It requires estimation of the correlation between sec-
ondary and primary endpoints, which is difficult for time to event endpoints like overall and progression
free survival. Moreover, Dmitrienko et al. [18] assume a multivariate t-distribution for the test statistics,
which is unsuitable for the corresponding log-rank tests. We therefore prefer to control type I error across
endpoints by the Bonferroni inequality.
6. Estimation of treatment effect
It is well known that the treatment selection process in this type of seamless designs can induce bias
in the final treatment effect estimate of the selected treatment(s). The literature on this topic has mostly
addressed the problem of estimation of the selected treatment means in designs where treatment selection
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is based on the rank order of the observed treatment effects of the primary outcome measure ([20–24]).
Carreras and Brannath [24] showed that the maximum selection bias is achieved when all experimental
treatments are equally efficacious, and in particular, when the global null hypothesis is true.
As treatment selection in the designs proposed in this article is based not on OS (primary endpoint) but
on drug exposure (surrogate endpoint), and the joint (asymptotic) distribution of primary and surrogate
endpoints is not known, no relevant theoretical results are available regarding bias or bias correction.
Therefore, we assess selection bias in the final estimate of the HR between the selected treatment and the
control via simulations.
Let 𝛽i = exp(𝜃i) be the HR between the i-th experimental treatment and the control. Let 𝛽i be the
estimate of 𝛽i; i = 1, 2, calculated at the end of the study. The selection bias for the estimate of the HR
in the comparison of the selected treatment to the control at the end of the study is given by b(𝛽S) =
E
[
𝛽S − 𝛽S
]
. In the simulations, we estimate b(𝛽S) by computing the average estimation error over all
simulation iterations.
Simultaneous (one-sided) confidence intervals that are consistent with the conservative Dunnett testing
procedure presented in Section 3.3 can be constructed. The lower confidence limits with joint confidence
coefficient 1 − 𝛼 for the two treatment effects 𝜃i are given by Uib + c1
√
Vib; i = 1, 2, where c1 is the
Dunnett’s critical value introduced in Section 5. No informative confidence intervals exist that are consis-
tent with the testing procedures introduced in Sections 3.1 and 3.2, when the hypothesis for the selected
regimen is rejected ([25, 26]).
7. Simulations
This section presents a simulation study that was performed to evaluate type I error, power and selection
bias in the proposed seamless phase II/III adaptive design using the three testing procedures described in
Sections 3.1, 3.2, and 3.3 as well as the treatment selection rules described in Section 4. We also compare
the seamless adaptive design to the standard design in which phases II and III are run in separate studies
as well as to the three-arm phase III design with regard to power. In order to compare the different designs
in a fair manner, we fix the total number of patients recruited in the simulated study as well as the date of
the final analysis. Note that, as long as recruitment rate is not data-driven, the conservative Dunnett and
the patient-wise procedures will protect type I error rate.
The simulation input presented in the next two sections represent variations of assumptions made in the
study protocol with regard to design characteristics such as recruitment rate, treatment allocation ratio,
sample size, median survival, mean exposure, timing of interim and final analyses, and so on. As it was
mentioned in the introduction, the study teamwas concerned that exposure of the low-dose regimen could
be too low to ensure sufficient treatment effect, and therefore, a high-dose regimen was incorporated in
the study. The team also expected the safety profiles of both regimens to be appropriate, and therefore,
exposure was considered to be the main decision driver at the interim treatment selection.
This simulation study attempts to answer two key questions: (i) Is there any advantage of using an
adaptive seamless design compared to a standard phase II + phase III design or a 3-arm phase III design?
and 2) Is there any gain in using exposure to make the treatment selection at the interim analysis compared
to a treatment selection based on OS?
7.1. Data generation
The study data for the seamless phase II/III adaptive design were generated in the following way. Study
enrollment was simulated using piece-wise uniform distributions assuming a total recruitment of 7
patients per month in the first 4 months, 15 patients per month in the following 4 months and 22 patients
per month thereafter. In the first stage of the study, patients were recruited in a 1:1:1 ratio to either exper-
imental arm or the control, respectively. After a certain number of patients across all three arms was
recruited (Section 7.2) and followed-up for at least 3 months, an interim regimen selection analysis was
performed in which one of the experimental treatments was selected to continue, together with control,
into the second stage. Patients in the second stage of the study were recruited in a 1:1 ratio to the selected
experimental arm and control, respectively. A total of 410 patients was recruited across both stages. The
final analysis was performed 29 months after the first patient was recruited. The one-sided significance
level was set to 𝛼 = 0.025. All data from both stages were used in the final testing of efficacy.
Survival timewas simulated for each patient in the study. Exposurewas simulated for each patient in the
experimental arms. The data generation for the experimental arms can be described using copulas [27].
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Let X be the survival time of a generic patient in one of the experimental arms, and let Y be his or her log
exposure. A copula function C relates the joint CDF, H(x, y) = P(X ⩽ x, Y ⩽ y), to the marginal CDF’s
F(x) and G(y) by H(x, y) = C(F(x),G(y)). For the present simulation, we chose F(x) = 1 − exp(−𝜆x)
the exponential CDF with rate 𝜆, G(y) = Φ( y−𝜇
𝜎
) the normal CDF with mean 𝜇 and variance 𝜎2 and
C(u, v) = Φ𝜌(Φ−1(u),Φ−1(v)), the normal copula, where Φ𝜌 denotes the bivariate normal CDF with
means 0, variances 1 and correlation 𝜌. Note that the normally distributed log-exposure assumption was
based on pharmacology experts’ opinion. Survival time for each patient in the control arm was generated
using an exponential distribution.
The study data for the design of the standard program running phase II separate from phase III were
generated in the same way as described earlier but the final testing of efficacy used only the data collected
on stage 2 patients.
The generation of study data for the three-arm phase III design was performed in a slightly different
way. A total of 410 patients was recruited across the three arms in a 1/1/1 treatment allocation ratio. There
was no interim regimen selection. Only the survival time for each patient was generated in this case.
Assumptions on study enrollment, timing of final analysis, distribution of survival times and significance
level were the same as before. The classical Dunnett test was used for the final testing of efficacy.
7.2. Scenarios
We considered the following combinations of median OS (in months) for high-dose (H), low-dose (L),
and control (C) arms and of mean exposure (in days×𝜇g∕mL) for high-dose and low-dose arms:
(1) Median OS (H, L,C) = (6, 6, 6) and mean exposure (H, L) = (300, 200).
(2) Median OS (H, L,C) = (9, 7.5, 6) and mean exposure (H,L) = (300, 175).
(3) Median OS (H, L,C) = (9, 7.5, 6) and mean exposure (H,L) = (300, 185).
(4) Median OS (H, L,C) = (9, 7.5, 6) and mean exposure (H,L) = (300, 200).
(5) Median OS (H, L,C) = (9, 7.5, 6) and mean exposure (H,L) = (300, 210).
(6) Median OS (H, L,C) = (9, 9, 6) and mean exposure (H, L) = (300, 200).
(7) Median OS (H, L,C) = (9, 9, 6) and mean exposure (H, L) = (300, 210).
We also considered all possible combinations of the following parameters:
(1) standard deviation for exposure (in days×𝜇g∕mL): 120 and 170;
(2) Copula correlation parameter 𝜌: 0.2, 0.5, 0.8, and 1;
(3) timing of interim analysis: after 100, 150, and 200 patients were recruited and followed for
3 months;
which resulted in a total of 168 simulation scenarios. In terms of data generation by the marginal
distributions F and G and copula C in Section 7.1, we have
𝜆 = ln(2)∕median(OS)
𝜇 = 2 ln(m) − 1
2
ln
(
m2 + 𝜏2
)
𝜎2 = ln
(
m2 + 𝜏2
)
− 2 ln(m)
(1)
where m is the mean exposure and 𝜏2 is the variance of exposure, exp(Y).
7.3. Simulation results
For every scenario described in Section 7.2, every testing procedure describe in Section 3 and every
treatment selection rule described in Section 4, we simulated 1 million trials and computed type I error,
power, probability of selecting the correct regimen, and selection bias. All graphs presented in this section
(except those of Figure 6) use the same line styles. Benchmark scenarios are presented in bold. The dotted
bold curve represents the perfect surrogate scenario described in Section 4.1. The dashed bold curve
represents the case where treatment selection is based on the primary endpoint, OS. The remaining (non-
bold) curves represent the approach where treatment selection is based on the surrogate endpoint, drug
exposure. In particular, the curves with plotting symbols given by two dots and one dash, two dashes and
one dot, three dots and one dash, and three dashes and one dot represent, respectively, the cases of copula
correlation parameter 𝜌 equal to 0.2, 0.5, 0.8, and 1.
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7.3.1. Type I error, power and probability of ‘correct’ treatment selection. Figure 2 presents the type I
error for testing the primary endpoint for the follow-up-wise (left graph), the patient-wise (middle graph),
and the conservative Dunnett (right graph) testing procedures.When treatment selection is based on expo-
sure (non-bold curves), we observe, as expected, a pattern of increased type I error with increased copula
correlation between exposure and survival. We also see that the perfect surrogate approach provides an
upper bound for the type I error probability. Type I error can be inflated for the follow-up-wise procedure
if treatment selection is based on exposure and the copula correlation between exposure and survival is
high. The patient wise and conservative Dunnett procedures control type I error as expected. The conser-
vative Dunnett procedure is the most conservative procedure, which provides some safeguards against
(minor) potential type I error inflation such as, for instance, due to changes in recruitment rate patterns
driven by the interim results.
In these simulations, power is defined as the probability to reject the selected primary null hypothesis
at the end of the study, which is correct as long as the selected treatment is more effective than con-
trol. Figure 3 presents power results for the conservative Dunnett procedure. Median OS of (H,L,C) =
(9, 7.5, 6)months, respectively, for the high-dose, low-dose, and control arms were assumed in all graphs.
Mean exposure,m in equation (1), was assumed to be 300 for the high-dose arm in all graphs. Mean expo-
sure of 175 (top-left graph), of 185 (top-right graph), of 200 (bottom-left graph), and of 210 (bottom-right
graph) were assumed for the low-dose arm. A standard deviation for exposure, 𝜏 in equation (1), was set
to 120 for both experimental regimens in all graphs. We observe that there is again a pattern of higher
power for higher copula correlation between exposure and survival, when treatment selection is based
on exposure. The performance of the treatment selection rule based on exposure depends strongly on the
probability to select the correct regimen (high-dose regimen in this case). For instance, the probability
of selecting the high-dose regimen was around 0.9, 0.78, 0.5, and 0.31, respectively, for the top-left, top-
right, bottom-left, and bottom-right graphs, when treatment selection was based on exposure and when
performing the treatment selection after 100 patients had been recruited and followed-up for 3 months
(see left graph of Figure 6). On the one hand, treatment selection based on exposure performs better with
regard to power than treatment selection based on OS in the two top graphs of Figure 3, independently of
the copula correlation between survival and exposure. On the other hand, power is dramatically decreased
in the two bottom graphs of Figure 3 when treatment selection is based on exposure compared to when
treatment selection is based on OS because the standardized difference in exposure between the treatment
groups is too small for a correct treatment selection with high probability. Hence, the performance of the
selection rule based exposure depends strongly on the standardized mean exposure difference between
the two dose regimens. We could conclude that the difference in exposure needs to be at least one stan-
dard deviation for treatment selection based on exposure to perform better than that based on OS. Note
that Figures 3 and 6 indicate that both the probability of selecting the high-dose regimen and power do not
depend strongly on the interim sample size. This means that, in this situation in which treatment selection
is based only on exposure or survival, treatment selection should be performed rather early during the
course of the study, thus avoiding unnecessary recruitment of patients to the non-selected arm (of course,
this argument may not apply to the situation in which treatment selection is also based, for instance, on
safety evidence). The other two testing procedures performed similarly with regard to power.
Figure 2. Type I error for follow-up-wise (left graph), patient-wise (middle graph), and conservative Dunnett
(right graph) procedures. Median OS (H,L,C) = (6, 6, 6), mean exposure (H,L) = (300, 200), and standard
deviation for exposure of 120 for all graphs.
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Figure 3. Power for the conservative Dunnett testing procedure. Median OS: (H,L,C) = (9, 7.5, 6) in all graphs.
Mean exposure of 300 for high-dose regimen. Mean exposure of 175, 185, 200, and 210 for the top-left, top-right,
bottom-left, and bottom-right graphs, respectively. Standard deviation for exposure of 120 for all graphs.
Power was considerably lower for the standard phase II + phase III design than for the seamless phase
II/III design, as Figure 4 shows. Because, in the standard phase II + phase III design, only stage 2 patients
are used in the final testing of efficacy at the end of the study, the copula correlation between exposure
and survival of stage 1 patients does not affect the power. We again observe that treatment selection
based on exposure performs better with regard to power than treatment selection based on OS in the two
top graphs of Figure 4 but power is dramatically decreased in the two bottom graphs of Figure 4 when
treatment selection is based on exposure compared to when treatment selection is based on OS. We can
conclude that, on the one hand, the seamless design is always preferred to the separate phase II + phase
III design, and on the other hand, the good or bad performance of the treatment selection rule based on
exposure remains the same whether a seamless design or a separate phase II + phase III design is used.
Power for the three-arm phase III design was 0.77 when median OS was set to (H,L,C) = (9, 7.5, 6)
months, respectively, for the high-dose, low-dose, and control arms, which is similar to the power that
was obtained with the seamless phase II/III design when treatment selection was based on OS. There-
fore, when the difference in exposure between the treatment groups is at least one standard deviation,
the seamless design with treatment selection based on exposure is preferred, from a power perspective,
compared to the 3-arm phase III design.
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Figure 4. Power for the separate phase II + phase III design. Median OS: (H,L,C) = (9, 7.5, 6) in all graphs.
Mean exposure of 300 for high-dose regimen. Mean exposure of 175, 185, 200, and 210 for the top-left, top-right,
bottom-left and bottom-right graphs, respectively. Standard deviation for exposure of 120 for all graphs.
Figure 5 presents power results for the conservative Dunnett procedure (left graph) and the separate
phase II + phase III design (right graph) for the following scenario in both graphs: median OS was
assumed to be (H,L,C) = (9, 9, 6) months, respectively, for the high-dose, low-dose, and control arms,
mean exposure of (H,L) = (300, 200), respectively, for the high-dose and low-dose arms and a standard
deviation for exposure of 120 was assumed. We observe again that the seamless design performs better
than the separate phase II + phase III design. In this scenario, because both experimental regimens are
equally effective, the correct regimen would be the low-dose regimen, which is expected to have a better
safety profile. The probability of selecting the low-dose regimen when treatment selection is based on
exposure is 0.5 in both graphs. We also considered a scenario in which mean exposure was assumed
to be (H,L) = (300, 210), respectively, for the high-dose and low-dose arms, and all other parameters
remained the same compared to the previous scenario. Power results for these two scenarios were, as
expected, very similar on the left graph and identical on the right graph, even though the probability of
selecting the low-dose regimen in the latter scenario was, for instance, 0.69 when treatment selection was
performed after 100 patients were recruited and followed up for at least 3 months. Once again, the other
two testing procedures performed similarly with regard to power in this case.
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Power for the three-arm phase III design was 0.88 when median OS was (H, L,C) = (9, 9, 6), which
was slightly lower than the power obtained with the seamless phase II/III adaptive design when treatment
selection was based on OS. This is reasonable because, when both experimental regimens are equally
effective, it is more efficient to select one of the two regimens quickly and use most of the patients for
the comparison of the selected regimen with the control.
Power results for the cases in which the standard deviation for exposure was increased to 170 were
similar to the corresponding results presented in this section. In Figure 6, we observe that, when treat-
ment selection was based on exposure, the probability of selecting the correct regimen slightly decreased
(increased) when mean exposure for the low-dose regimen was smaller (larger) than 200 in the case
of standard deviation for exposure of 170 compared to the case of standard deviation for exposure
of 120.
The aforementioned discussion about power provides only a narrow view of the main objective of the
study. The objective should not really be maximizing the power at all costs but rather to find the correct
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Figure 5. Power for the conservative Dunnett testing procedure (left graph) and for the separate phase II +
phase III design (right graph). Median OS: (H,L,C) = (9, 9, 6) in both graphs. Mean exposure of 300 and 200,
respectively, for high-dose and low-dose regimens. Standard deviation for exposure of 120 for both graphs.
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Figure 6. Probability to select the high-dose regimen when treatment selection is based on exposure. Mean expo-
sure of 300 was assumed for the high-dose regimen in both graphs. Standard deviation for exposure was assumed
to be 120 and 170, respectively, on the left and right graphs. Probabilities were obtained by simulations using a
grid of mean exposures for the low-dose regimen from 170 to 220 in steps of 5.
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dose regimen; that is, the regimen that provides an appropriate efficacy at the lowest feasible dose. Indeed,
in the case study, the default preference is for the low-dose regimen, which is the standard regimen in
MBC and for which the safety profile is well established. Having this in mind, one relevant question is:
what is the probability of selecting the correct regimen at the interim analysis? This, of course, depends
on the considered scenario, on the treatment selection rule and (though slightly) on the number of patients
included in the interim analysis. For instance, in the scenarios in which median OS is (9, 7.5, 6) months
for the high dose, low dose and control respectively, mean exposure for the high-dose regimen is 300
and standard deviation for exposure is 120, we would need to have a (true) mean exposure for the low-
dose of 185 or smaller in order to select the correct (high-dose) regimen with 0.8 or larger probability,
when treatment selection is based on exposure and interim analysis is performed after 100 patients have
been recruited and followed for 3 months (see left graph of Figure 6). Increasing the interim sample
size up to 200 patients does not much improve the probability of a correct selection. Another relevant
question is, how much does the probability of selecting the correct dose regimen increase if we waited
until the end of the study to make the treatment selection (3-arm phase III design)? The probability of
selecting the correct regimen (based on OS) at the end of the trial when median OS is assumed to be
(9, 7.5, 6)months respectively for the high-dose, low-dose and control treatments is 0.89, which is higher
than the probability of selecting the correct regimen at interim analysis based on OS, when treatment
selection is performed after 100, 150 and 200 patients are recruited and followed for 3 months, which
is, respectively, 0.69, 0.73 and 0.77. Note that interim treatment selection based on exposure has the
potential of improving the probability of selecting the correct regimen, and therefore, the power of the
study (see two top graphs in Figure 3 ).
7.3.2. Selection bias. Selection bias is defined as the expected difference between the estimated and
the true HR for the comparison of the selected regimen with the control at the end of the study [28].
In this definition, both the estimated and true HRs are random variables because of the data driven
selection process. Selection bias comes from the fact that the selection process may tend to choose a
regimen when its HR estimate is by chance smaller than expected. One example is when treatment
selection is based on the HR for OS and both experimental regimens are equally effective. In this case,
selecting the treatment that by chance has the smallest HR at the interim analysis and then reporting
the estimated HR for this regimen will clearly overestimate the true HR. When one of the experimen-
tal regimens is more effective than the other, it will be more likely to select the most effective regimen
at the interim analysis, but there will still be instances in which the least effective regimen will by
chance have a smaller estimated HR than that of the most effective regimen. In this case, it is likely
that the estimated HR of the (selected) least effective regimen will be an overestimation of its true
HR. This will cause a negative bias. Similar arguments to those described earlier can be made when
the regimen selection is based on exposure and the copula correlation between exposure and survival
is high.
The most relevant selection bias results are presented in Figure 7 (results are the same for all testing
procedures as bias is affected by the treatment selection rule but not by the testing procedure). Median
OS was 6 months for all treatments (left graph). Median OS was 9, 7.5, and 6 months (middle graph)
and 9, 9, and 6 months (right graph), respectively, for the high-dose, low-dose, and control arms. Mean
exposure was assumed to be 300 and 200, respectively, for the high-dose and low-dose arms and standard
deviation for exposure was assumed to be 120 in all graphs. We observe an expected pattern of larger
(negative) bias for higher copula correlation between survival and exposure, when regimen selection is
based on exposure.
In practice, neither the treatment effects nor the mean and standard deviation for exposure will be
known. Therefore, one option would be to correct the final estimate of the treatment effect for the maxi-
mum bias observed in some plausible simulated scenarios. In our simulations, the worst bias was between
−0.017 and −0.025 depending on the number of patients recruited before the interim analysis. (See left
graph of Figure 7 for treatment selection rule based on exposure and copula correlation parameter 𝜌 equal
to 1. Bias was less severe in all other scenarios.) As an example, suppose that the interim analysis took
place after 100 patients were recruited and supposed that the estimated HR for the comparison of the
selected treatment to the control at the end of the study was, say, 0.67. Then, this estimated HR should
be corrected to 0.69.
Copyright © 2015 John Wiley & Sons, Ltd. Statist. Med. 2015
M. CARRERAS, G. GUTJAHR AND W. BRANNATH
Figure 7. Selection bias. Median OS: (H,L,C) = (6, 6, 6) (left graph), (H,L,C) = (9, 9, 6) (middle graph), and
(H,L,C) = (9, 7.5, 6) (right graph). Mean exposure of (H,L) = (300, 200) and standard deviation for exposure of
120 was assumed in all graphs.
8. Conclusions
In this article, we have discussed the planning of an oncology clinical trial with a seamless phase II/III
adaptive design. Three testing procedures were considered. The standard follow-up-wise testing proce-
dure that combines stage-wise p-values based on the independent increments property of the log-rank
statistic (Schäffer & Müller [7], Wassmer [10]) did not protect the type I error when treatment selection
was based on exposure and correlation between exposure and survival was high. One possibility would
be to adjust the significance level to achieve type I error control to the specified level 𝛼 for the perfect
surrogate approach suggested in Section (4.1), which provides an upper bound for the type I error. This
adjustment will of course affect the power of the study. The patient-wise testing procedure proposed by
Jenkins et al. [9] protects the type I error when testing the primary endpoint as long as the follow-up of
stage 1 patients remains unchanged after the regimen selection analysis, which may be difficult to achieve
in practice. If, for instance, it is decided to discontinue treatment in the dropped arm (e.g., for ethical
reasons), this may have an impact on the type I error rate: (i) because the p-value for the comparison of
the dropped regimen with the control may no longer be uniformly distributed under the null hypothe-
sis (if, e.g., these patients drop out and obtain an alternative treatment) and (ii) because this adaptation
may affect the time point of the final analysis. The conservative Dunnett test procedure protects the type
I error without placing any strong restrictions to the study design. It only requires that the recruitment
of the second stage patients is independent from the interim data. It can also be extended to a procedure
for testing primary and secondary endpoints, which protects the multiple type I error rate. Moreover, its
conservatism provides a safeguard against unintended type I error inflations, for instance, due to unin-
tended changes in the recruitment rate. Changes to treatment and/or follow-up of patients in the dropped
arm do not affect the type I error as these patients are not used in the final analysis. The conservative
Dunnett test also allows construction of simultaneous confidence intervals. A disadvantage of the Dun-
nett procedure is that it does not permit data driven changes of the preplanned overall event number. All
three procedures have similar performance with regard to the power to reject the primary hypothesis for
the comparison of the selected treatment to the control at the end of the study.
We have not found a clear advantage with regard to power in using adaptive designs compared to a
three-arm phase III design. However, even though the probability of correct treatment selection is max-
imized with the three-arm phase III design, an adaptive design allows us to select a treatment early,
avoiding an unnecessary large recruitment of patients to the non-selected arm, which is important from
an ethical and practical point of view. If efficacy differences in survival are reflected by substantial differ-
ences in exposure, then a selection rule based on exposure can improve power compared to a rule based
on survival only. However, power could be dramatically reduced when the surrogate endpoint is not able
to select the correct treatment with high probability, independently of how highly correlated the primary
and surrogate endpoints may be. A solution to this problem could be selection rules that incorporate both
exposure and the immature primary endpoint. How to combine these two endpoints in a sensible selec-
tion rule is an interesting open research question. Treatment selection rules should always include the
primary endpoint independently how immature the primary endpoint may be. In practice, selection rules
will also incorporate safety parameters such as overall death rates, adverse events, serious adverse events,
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treatment withdrawals, and exposure to treatment, which may be important drivers in the dosing deci-
sion. One design feature we have not considered in our investigation is the possibility to continue with
both experimental arms to the end of the study if interim results do not show a clear advantage for one or
the other. In this situation, the conservative Dunnett procedure could inflate the type I error because the
overall number of events could not be pre-fixed.
Selection bias in the settings described in this paper was found not to be a serious problem. This may
be related to the fact that only two experimental treatments are compared to a control and that the interim
analysis is performed relatively early in the study. (Naturally, selection bias increases with an increased
number of patients used at the treatment selection analysis as well as with a larger number of experimental
treatments being compared.)
Finally, in order to minimize the risk of operational bias, it is important to restrict the knowledge
of interim results as well as of detailed interim decision-making rules to the iDMC and potentially to
a reduced number sponsor personnel that is not involved with the conduct of the study. However, as
this study is open label, investigators may be subjectively influenced by the knowledge of the selected
treatment regimen, and, therefore, operational bias cannot be completely ruled out. The sponsor should
provide evidence that patients have been treated, managed, and evaluated according to the protocol
throughout the entire study.
Appendix A. Example of FWER inflation for testing procedure 2
A.1. Example of family-wise error rate inflation
The following example shows that the closed testing procedure for testing the primary hypotheses
exhausts the 𝛼 level when the regimen selection rule can vary arbitrarily.
Let I ⊆  be the set of true null hypotheses. Assume that H11 ∉ I and H12 ∈ I. Assume also that
H21 ∈ I. If the effect of regimen 1 for the primary endpoint is very large, we can assume that H11 and
H11 ∩H12 can always be rejected. Consider the following regimen selection rule: ‘select regimen 2 only
when H12 and H11 ∩ H12 can be rejected at level 𝛼. Otherwise, select regimen 1’. Then,
FWER ⩾ P
(
{Reject H12} ∪ {Reject H21}
)
= P({Reject H12} | select regimen 2)P(select regimen 2)
+ P({Reject H21} | select regimen 1)P(select regimen 1)
= 1 × 𝛼 + 𝛼′ × (1 − 𝛼) > 𝛼
The aforementioned result is true for any level 𝛼′ with which we test the secondary hypotheses. The
aforementioned argument works when the regimen selection is performed at the end of the study. Oth-
erwise, it is not possible to know for sure that H12 will be rejected at the end of the study when the
regimen selection is performed at an interim analysis. But, some error inflation must be expected when
the regimen selection is performed at the interim analysis. Of course, this example is based on an extreme
regimen selection rule as well as on extreme assumptions about the effects of the two regimens for the
different endpoints. But, as the actual regimen selection rule and treatment effects in the study are not
known, we cannot rule out a potential FWER inflation.
Appendix B. Proof of FWER control for testing procedure 3
Define Dunnett’s critical value c1 for the primary hypotheses so that PH11∩H12(T11 ∨ T12 < c1) = 𝛼. Set
𝛼1 = Φ(c1) and 𝛼2 = 𝛼 − 𝛼1, with an associated critical value c2 = Φ−1(𝛼2). Then 𝛼1 > 𝛼2, because
𝛼2 = PH11∩H12
(
{T11 < c1} ⧵ {T12 < c1}
)
⩽ PH11(T11 < c1) = 𝛼1,
and therefore
PH21∩H22(min{T21,T22} < c2) ⩽ 2𝛼2 ⩽ 𝛼1 + 𝛼2 = 𝛼 (B.1)
We can now verify that the FWER 𝜉 is controlled by enumerating the possible cases for the set I ⊆
{H11,H12,H21,H22} of true null hypotheses (i, j ∈ {1, 2} with i ≠ j):
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(1) If H1i ∈ I and H1j ∈ I, then 𝜉 = PH11∩H12(min{T11, T12} < c1) = 𝛼.
(2) If H1i ∈ I and H1j ∉ I, distinguish two cases:
(a) If H2j ∈ I, then 𝜉 ⩽ PH1i∩H2j
(
{T1i < c1} ∪ {T2j < c2}
)
⩽ 𝛼1 + 𝛼2 = 𝛼.
(b) If H2j ∉ I, then 𝜉 = PH1i(T1i < c1) = 𝛼1 < 𝛼.
(3) If H1i ∉ I and H1j ∉ I, distinguish three cases:
(a) If H2i ∈ I and H2j ∈ I, then 𝜉 ⩽ 𝛼 by Equation (B.1).
(b) If H2i ∈ I and H2j ∉ I, then 𝜉 ⩽ PH2i(T2i < c2) = 𝛼2 < 𝛼.
(c) If H2i ∉ I and H2j ∉ I, then I = ∅ and 𝜉 = 0.
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